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Objective – Atherosclerosis is caused by the accumulation of LDL at atherosclerosis-
susceptible sites. This requires LDLs to pass through the endothelium and be retained 
in the arterial intima, but which process is rate-limiting and predicts atherosclerosis 
has remained controversial. To answer this question, we performed high-resolution 
mapping for LDL entry and retention in healthy, pre-atherosclerotic and atherosclerotic 
mouse arteries.  
Approach and Results – Rates of LDL entry and retention were measured by 
injecting fluorescent LDL into mice followed by en face scanning and whole-mount 
confocal microscopy of the aortic arch after 1 hour (entry) and 18 hours (retention). 
Measurements were performed in groups of pre-atherosclerotic mice after short-term 
hypercholesterolemia and in normocholesterolemic mice with a similar clearance rate 
of the fluorescent LDL probe. We found that rates of LDL entry and retention under 
normal and pre-atherosclerotic conditions are dissociated and divide the aortic arch 
into three zones: an outer arch zone with low LDL entry and LDL retention, and 
subdivisions of the inner arch region consisting of a border zone with high LDL entry 
and high LDL retention and a central inner arch zone with intermediate LDL entry and 
saturable LDL retention. These characteristics predicted susceptibility to 
atherosclerosis, which was low in the outer zone, high in the border zone, and 
intermediate in the central inner zone. Saturation of LDL retention in the central inner 
zone was intrinsic to the arterial wall and was lost with the onset of atherosclerosis. 
Conclusion – Rates of LDL entry and retention in arteries are dissociated and 
provide distinct information on atherosclerosis susceptibility. Combined, they predict 
where and when atherosclerosis develops in the mouse aortic arch.  






































    
 
Objetivo – La aterosclerosis está causada por la acumulación de partículas de LDL 
en regiones de la pared arterial más susceptibles a esta enfermedad. Para ello, se 
requiere que las LDL atraviesen el endotelio y sean retenidas en la íntima arterial, 
pero qué proceso actúa como limitante y es capaz de predecir el desarrollo de la placa 
sigue resultando controvertido. Para responder a esta pregunta, realizamos un mapeo 
de alta resolución a partir de la entrada y de la retención de LDL en arterias de ratón 
sanas, pre-ateroscleróticas y ateroscleróticas. 
Métodos y Resultados – Se midieron las tasas de entrada y de retención de LDL 
inyectando LDL fluorescente en ratones. A continuación, se realizó un escaneo en 
face de la aorta, así como microscopía confocal de preparaciones del arco aórtico 
completo después de 1 hora (entrada) y 18 horas (retención) de circulación del LDL. 
Las mediciones se realizaron en grupos de ratones pre-ateroscleróticos después de 
un breve estado de hipercolesterolemia, y en ratones normocolesterolémicos con una 
ratio similar de eliminación de la sonda de LDL fluorescente. Encontramos que las 
tasas de entrada y de retención de LDL en condiciones normales y pre-
ateroscleróticas se disocian y dividen el arco aórtico en tres zonas: una zona del arco 
externo con baja entrada y retención de LDL, y subdivisiones de la región del arco 
interno, una zona fronteriza con alta entrada y retención de LDL, y una zona central 
interna con entrada moderada de LDL y retención saturable. Estas características 
predijeron la susceptibilidad a la aterosclerosis, que fue baja en la región externa, alta 
en la región fronteriza e intermedia en la zona interna central. La saturación de la 
retención de LDL en la zona interna central era intrínseca a la pared arterial y se 
perdió con el inicio de la aterosclerosis.  
Conclusión – Las tasas de entrada y de retención de partículas de LDL en la arteria 
están disociadas y proporcionan información clara sobre la susceptibilidad a la 
aterosclerosis. Combinadas, permiten predecir dónde y cuándo se desarrolla la 
aterosclerosis en el arco aórtico del ratón. 
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1.1. Atherosclerosis  
Cardiovascular diseases (CVDs) are the main cause of death worldwide, 
accounting for 17.9 million deaths per year (31% of global deaths) (WHO). The 
majority of CVDs are attributed to atherosclerosis where the development of 
thrombosis may obstruct blood flow to the heart (coronary heart disease), brain 
(ischemic stroke), or lower extremities (peripheral vascular disease).1 Most people do 
not know, but atherosclerosis already starts acting during our teenage years. So, 
during our adolescence, while fighting psychological and social changes, we are 
unconsciously dealing with an invisible killer that slowly progresses over decades. The 
atherosclerotic lesions remain innocuous for many years but the longer you live, the 
higher is the probability of undergoing its clinical complications. For this reason, the 
increasing average age of the population from the beginning of the 20th century led 
atherosclerosis to be a central player in the CVDs mortality rates in the world.2 
Because population growth and the average lifespan are expected to increase 
further, the identification of preventive measures against the development of 
atherosclerosis is of great importance.  
 
1.1.1. Low-Density Lipoproteins (LDL)  
Atherosclerosis is a multifactorial disease initiated and sustained by multiple 
risk factors, including a high plasma level of low-density lipoproteins (LDLs) and other 
Apolipoprotein B (ApoB)–containing lipoproteins, arterial hypertension, diabetes 
mellitus, smoking, and psychosocial factors.3 Most individuals that develop clinical 
symptoms of atherosclerosis have been exposed to several of these risk factors; 
however, an increased plasma concentration of LDL - compared with the physiological 
level of 0.5-1 mM present in newborns and other mammals4 - represents a particularly 
important risk factor. Increased LDL is necessary and sometimes sufficient to cause 
atherosclerosis. None of the other risk factors alone can cause the development of the 
disease.  
Indeed, monogenic hypercholesterolemias, caused by single gene mutations in 
genes involved in LDL clearance, are associated with high risk of atherosclerosis.5 
Familial hypercholesterolemia (FH), the most common and most severe form of 
monogenic hypercholesterolemia, is caused by mutations in the Low-Density 
Lipoprotein Receptor (LDLR) gene. Patients with FH exhibit very high LDL plasma 
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levels irrespective of diet and lifestyle, and FH homozygotes develop aortic and 
coronary atherosclerosis already in childhood.6 Conversely, life-long reduced levels of 
LDL, caused by variants in the genes for Proprotein convertase subtilisin/kexin type 9 
(PCSK9) or LDLR that increase LDL clearance, is a powerful protectant against 
atherosclerosis.4  
In addition, clinical trials showed that LDL lowering treatments (e.g. statins, 
ezetimibe, or PCSK9 inhibitors) in adult patients with established atherosclerosis 
significantly reduce atherosclerotic cardiovascular events even in the presence of 
other risk factors, supporting the crucial role of increased LDL plasma levels not only 
in atherosclerosis initiation but also in lesion progression.4,7  
The causal link between blood cholesterol and atherogenesis was unveiled 
already by Ignatowski and Anitschkow between 1908-1913.8,9 Their pioneering work 
in cholesterol-fed rabbits that developed atherosclerosis was the birth of the 
“cholesterol hypothesis” for atherosclerosis and the first of many experimental studies 
investigating the initiating events in atherosclerosis. Indeed, many researchers have 
since shown that atherosclerosis can be induced in animals that do not spontaneously 
develop atherosclerosis (such as rabbits, mice, rats, guinea pigs, hamsters, birds, 
dogs, and non-human primates) by increasing the level of LDL or other ApoB–
containing lipoproteins via feeding atherogenic diets or genetic modification.10 It is also 
now clear that cholesterol per se is not pathogenic as the increased plasma 
concentration of other cholesterol transporters, such as high-density lipoproteins 
(HDL) and erythrocytes, does not cause atherogenesis.11 
 
1.1.2. Atherosclerosis-prone sites 
The artery wall consists of three layers: arterial intima (innermost layer), arterial 
media (the middle layer) and adventitia (outermost layer). The arterial intima has a 
single layer of endothelial cells (ECs), in contact with the bloodstream, and a sub-
endothelial layer of connective tissue. The sub-endothelial space comprises scattered 
vascular smooth muscle cells (VSMCs), resident dendritic cells (DCs), resident 
macrophages and an extracellular matrix (ECM) that is rich in elastic fibers and 
proteoglycans. The intima is separated from the arterial media by the internal elastic 
lamina, composed of fenestrated elastic fibers. The arterial media consists of multiple 
layers of VSMCs and ECM rich in elastic tissue, collagen, and proteoglycans and it is 
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separated from the adventitia by the external elastic lamina. The adventitia consists of 
connective tissues with collagen, elastic fibers and interspersed fibroblasts, VSMCs, 
DCs and macrophages.12,13  
The luminal surface of blood vessels is exposed to hemodynamic shear stress, 
which is defined as the force that the blood flow exerts on the vessel wall. Straight 
artery segments, such as the common carotid artery (CCA), are exposed to uniform 
and unidirectional laminar flow with high shear stress (higher than 12 dyne/cm2). Part 
of vessel bifurcations and the inside of vascular curvatures are subjected to disturbed 
blood flow with low shear stress and directional changes (±4 dyne/cm2).14 In humans, 
these areas often develop a thickened arterial intima and they are the sites where the 
first lesions develop and where most culprit lesions causing clinical disease are 
located. Sites of the arterial tree in which lesions are initiated are defined as 





The importance of altered blood flow in lesion development was recognized by 
Caro et al. already in 1969.15 Since then, numerous studies have reported the 
important connection between disturbed blood flow and the initiation and development 
of atherosclerosis.16 In hypercholesterolemic mice, a causal relationship has been 
demonstrated by the placement of a mildly constrictive perivascular collar in the 
Figure 1. Atherosclerosis-prone sites and 
blood flow. In the thoracic aorta, the 
atherosclerosis-prone sites (APS) (dark pink) 
correspond to branch points and the inner 
curvature region of the aortic arch, which are 
subjected to low shear stress because of 
disturbed blood flow (green circle). The straight 
segments (outer curvature and descending aorta) 
are subjected to high shear stress because of 
unidirectional laminar blood flow (green arrows). 
 
   
 4 
common carotid artery.17 The straight portion of the common carotid artery is normally 
fully protected from atherosclerosis development, but the disturbed blood flow that 
results from the insertion of the collar transforms it to an atherosclerosis-prone site 
with rapid lesion formation.17  
Why the atherosclerosis-prone sites at branch points and curvatures have a 
particular susceptibility towards developing atherosclerosis when LDL levels are high 
is not yet understood and is the overall topic of the present thesis. As described in the 
following sections, there are multiple steps in the mechanism by which LDL initiate 
atherogenesis: LDL entry into the artery wall, LDL retention in the sub-endothelial 
space, LDL modification, and a maladaptive inflammatory response to the 
accumulated modified LDL (Figure 2). Topographical differences in the activity of 
these sub-mechanisms are clear candidates for regulating atherosclerosis 




Figure 2. Steps by which LDL initiate atherogenesis. Plasma LDL cross the endothelium by 
transcellular route or paracellular route (LDL entry) and they become retained by binding to intimal 
proteoglycans (LDL retention). Once retained in the sub-endothelial space, LDL are modified through 
oxidation or aggregation (LDL modification) and modified-LDL act as chronic stimulators of the innate 
and adaptive immune systems, triggering a maladaptive inflammatory response. EC= endothelial cell, 
SR= Scavenger receptor. 
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1.1.3. LDL entry in the artery wall  
The development of atherosclerosis is triggered by the accumulation of ApoB-
containing lipoproteins, mainly LDL, in the arterial intima. Therefore, LDL must cross 
the arterial endothelium from the bloodstream and enter the sub-endothelial space. 
Yet the precise mechanisms underlying this trans-endothelial flux of LDL into the 
arterial wall has been the subject of debate for decades.18,19 LDL can cross the 
endothelial monolayer by passing between adjacent cells (paracellular route) or by 
passing through the cytoplasm of individual cells (transcellular route or transcytosis).20 
Electron microscopic studies favor the latter route, showing the internalization of LDL 
into cellular vesicles (caveolae), while the transit of LDL through intercellular junctions 
is not conspicuous.21 Also, the size of LDL (over 20 nm) would require the loosening 
of inter-endothelial junctions for the paracellular route to occur;22 yet early 
atherosclerotic lesions display an intact endothelium.23 Some investigators sustain the 
paracellular route as the main LDL transport route, suggesting that LDL exit the 
bloodstream at areas of damaged or dividing endothelium.24,25 Although the rate of 
endothelial mitosis is very low (lower than 0.05%)22 and endothelial apoptosis or 
denudation is not typical in early stages of atherosclerosis,23 it may only take a few of 
such breaches to facilitate intimal LDL accumulation.26 In summary, the route by which 
LDL cross the endothelium is controversial, but current evidence for the early stages 
of atherosclerosis initiation favor transcytosis. In advanced lesions, other routes could 
acquire additional importance. 
 
1.1.3.1. Endothelial LDL transcytosis  
Transcytosis can be divided into two main types of processes. In direct 
transcytosis, macromolecules are transported directly from the luminal side to the 
basolateral side of endothelial cells (i.e. caveolae-mediated transcytosis) facilitated by 
specific binding to endothelial receptors or via fluid-phase or non-specific binding to 
membranes.27 In indirect transcytosis, macromolecules are endocytosed into early 
endosomes, transferred to recycling endosomes, and exocytosed on the basolateral 
side of endothelial cells (i.e. LDLR-mediated transcytosis).27  
The identification of endothelial receptors involved in arterial LDL transcytosis 
is of high importance, because their regulation may determine susceptibility to 
atherosclerosis and be target for therapy. Several lines of evidence suggest that 
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transcytosis of LDL across ECs of the systemic circulation is independent from the 
high affinity LDL receptor, despite its implication in LDL transcytosis across the blood-
brain barrier.28 It has been shown that the methylation of ApoB, which inhibits its 
recognition by LDLR, does not affect LDL entry in the arterial wall in rabbits.29 Also, 
PCSK9-mediated LDLR degradation has no effect on LDL transcytosis in primary 
human coronary artery endothelial cells (HCAECs).30 Instead, the Scavenger receptor 
class B type 1 (SR-B1) and the Activin receptor-like kinase 1 (ALK-1) have both been 
identified as LDL transcytosis-mediators in ECs of the systemic circulation.  
SR-B1, known as a high affinity HDL receptor, has been shown to be able to 
bind native LDL.31 In HCAECs, LDL colocalizes with SR-B1 and its overexpression 
increases LDL transcytosis, while its knockdown has the opposite effect.30 
Competition with an excess of HDL also decreases LDL transcytosis30. The implication 
of SR-B1 in LDL transcytosis was also demonstrated by lower intimal accumulation in 
aortas from SR-B1-deficient mice after ex vivo perfusion with fluorescently-labeled 
LDL, compared with wild-type mice.30 The signaling pathway downstream of SR-B1 is 
starting to be deciphered and involves the association of the guanine nucleotide 
exchange factor (GEF) Dedicator of cytokinesis 4 (DOCK4) with the C-terminal 
cytoplasmic tail of SR-B1, with subsequent activation of GTPase Rac1 and recruitment 
of its downstream effectors.32 
ALK-1 is a member of the Transforming growth factor beta (TGF-β) receptor 
superfamily and was identified as a low-affinity high capacity receptor for LDL.27 As 
SR-B1, ALK-1 colocalizes with LDL and its overexpression increases while knockdown 
decreases LDL transcytosis.33 Moreover, the endothelium-specific knockout of Alk1 in 
Ldlr knockout mice leads to reduced fluorescently-labeled LDL accumulation in the 
aortic endothelium.33 
Both SR-B1 and ALK-1 have been reported to reside in caveolae,34,35 small 
bulb-shaped plasma membrane invaginations of ∼50–80 nm in diameter that are 
enriched in cholesterol and sphingolipids and able to undergo endocytosis.27 Caveolin-
1 (CAV-1) is the main protein constituent of caveolae, and it has been shown to play 
a role in atherogenesis. CAV-1 deficiency in Apolipoprotein E deficient (Apoe -/-) mice 
reduces atherosclerotic lesions, while endothelial CAV-1 re-expression promotes 
lesion expansion.36,37 The genetic ablation of CAV-1 results in impaired arterial LDL 
transcytosis in mice, suggesting caveolae-mediated transcytosis as a major regulator 
of LDL entry into the vessel wall.38 
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1.1.4. LDL retention in the artery wall  
LDL normally flux into the arterial wall, most likely by transcytosis, and efflux 
back into the bloodstream. Therefore most LDL particles that enter the artery wall, 
leave without contributing to the intimal LDL accumulation that finally triggers 
atherosclerosis.39 Indeed, after decades of research there is now a large body of 
evidence to support the “response-to-retention hypothesis” of atherogenesis.23 This 
hypothesis states that the retention of ApoB-containing lipoproteins, mainly LDL, in the 
intimal extracellular matrix is a key mechanism in intimal LDL accumulation and 
atherosclerosis. It builds on pioneering work performed between the 1940s and 1980s, 
which collectively demonstrated that LDL interact with proteoglycans (PGs) of the 
artery wall.40–42 
LDL consist of a lipid core of triacylglycerols and cholesteryl esters, surrounded 
by a layer of phospholipids, unesterified cholesterol and apolipoproteins. ApoB is the 
main apolipoprotein of LDL and human LDL contain a single copy of ApoB100 (4536 
amino acids). In mice, many LDL instead have the truncated form of ApoB called 
ApoB48, which is also the form found in intestinally-derived lipoproteins.43  
Proteoglycans are complex macromolecules that, together with elastin and 
collagens, constitute the intimal extracellular matrix44. Vascular proteoglycans are 
composed of a core protein and one or more covalently attached glycosaminoglycans 
(GAGs), linear polysaccharides consisting of repeating disaccharide units of 
chondroitin sulfate (CS), heparan sulfate (HS), dermatan sulfate (DS) or keratan 
sulfate (KS).43 Proteoglycans are negatively charged due to the sulfate and carboxylic 
acid groups in their GAG side-chains. The artery wall proteoglycans include versican, 
perlecan, decorin, biglycan, and syndecan-4.43 
During the first steps of atherogenesis, the negatively charged GAG chains of 
the arterial intimal proteoglycans bind LDL via ionic bonds to positively charged 
aminoacyl residues on ApoB (Figure 3). These sites have been mapped and are 
located in site B-Ib (residues 84-94)45 in ApoB48 and in site B (residues 3359-3369)46 
and site A (residues 3148-3158)47 in ApoB100, the latter only being exposed when 
LDL is modified by secretory phospholipase A2 (sPLA2).47 In addition, ApoB48-LDL 
typically contain numerous molecules of ApoE, presenting a proteoglycan-binding 
domain almost identical to site B of ApoB100.11 Most proteoglycans have been 
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demonstrated to bind to LDL in vitro.46,48 However, biglycan and perlecan seem to be 


















LDL retention in the sub-endothelial space of the arterial intima seems to be 
strongly dependent on the intrinsic characteristics of lipoproteins and on the capacity 
of the vessel wall to bind them. Atherogenicity of LDL particles in terms of affinity for 
proteoglycans is modulated by their lipid and protein composition. The surface lipid 
composition50 and the lipid core composition47 affect the conformation of ApoB and 
therefore the LDL-proteoglycan interaction. Regarding the protein composition, it has 
been shown that the Apolipoprotein-C (ApoC)-III levels within LDL alter their 
proteoglycan-binding affinity. The mechanism is not clear, but an increased ApoC-III 
content, which itself lacks proteoglycan-binding sites, may induce conformational 
changes that render ApoB and/or ApoE more accessible to proteoglycans.51 
Atherogenicity of proteoglycans is modulated by the cellular environment. Elongated 
GAG chains and GAG sulfation pattern with higher 6:4 position sulfation ratio in the 
disaccharide units have been associated with increased proteoglycan/LDL binding.52 
These atherogenic changes in the GAG chains of proteoglycans are influenced by 
numerous factors including growth factors (i.e. platelet-derived growth factor and 
transforming growth factor-β), hormones (i.e. angiotensin II), and metabolic factors 
(i.e. oxidized LDL and free fatty acids).52 
 
Figure 3. Structure of proteoglycans and 
LDL-proteoglycan interaction. The 
negatively charged glycosaminoglycan 
side chains of the arterial intimal 
proteoglycans (versican, perlecan, decorin, 
biglycan, and syndecan-4) bind LDL via 
ionic interactions to positively charged 
aminoacyl residues on ApoB.  
(Based on Fogelstrand and Borén, 2012)43 
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1.1.5. Response to LDL retention and atherosclerosis initiation 
Once retained in the sub-endothelial space of the arterial intima, LDL may be 
subjected to multiple enzymatic and non-enzymatic chemical modifications. Free 
oxygen radicals, hydroperoxides, and lipoxygenases cause oxidization of LDL 
(oxLDL), and lipolytic enzymes such as lipoprotein lipase (LPL), sPLA2, and secretory 
sphingomyelinase (sSMase) expose additional proteoglycan-binding sites of ApoB 
and cause LDL aggregation.47,53,54 The LDL-proteoglycan binding per se also induces 
a physical alteration of LDL with changes in their lipid organization and ApoB 
configuration that make proteoglycan-bound LDL more susceptible to oxidation and 
aggregation.55,56  
The retained and modified LDL acquire molecular patterns shared with 
microbes (microbe-associated molecular patterns, MAMPs) and damaged tissue 
(danger-associated molecular patterns, DAMPs) that make them recognizable by the 
immune response.57 Modified-LDL therefore act as chronic stimulators of the innate 
and adaptive immune systems, triggering a maladaptive inflammatory response. 
Indeed, they induce in ECs and VSMCs the activation of pro-inflammatory pathways 
such as the nuclear factor-κB (NF-κB) pathway and the expression of adhesion 
molecules (i.e. vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion 
molecule 1 (ICAM-1)) and chemoattractants (i.e. monocyte chemoattractant protein-1 
(MCP-1)) that stimulate the attachment and transmigration of monocytes into the 
intimal space. Here, monocytes differentiate into macrophages and dendritic cells.58–
60 These, together with resident VSMCs, engulf modified LDL through scavenger 
receptors (SR) (i.e. scavenger receptor A (SRA), CD36, SR-B1 and low-density 
lipoprotein receptor 1 (LOX1)) and possibly other mechanisms, becoming foam cells.61 
Foam cell formation stimulates the release of pro-atherogenic factors that induce the 
synthesis of elongated proteoglycans with enhanced affinity for atherogenic 
lipoproteins, pro-inflammatory cytokines (i.e., interleukin-1β and tumor necrosis factor-
α) and pro-retentive enzymes (LPL, sSMase, and sPLA2) that promote further 
retention and modification of LDL and aggravation of the vascular inflammation.11 
Eventually T cells and other inflammatory cells enter the intima and contribute to the 
inflammatory response.59 Accumulated foam cells in several layers give rise to 
xanthomas that can then develop into progressive atherosclerotic lesions.1 
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LDL retention and oxidation may be a self-enhancing process in which retained 
modified LDL elicit cellular responses that lead to additional LDL entrapment. Ox-LDL 
stimulate vascular smooth muscle cells to proliferate and secrete proteoglycans with 
elongated GAG chains presenting increased affinity for LDL.62 Furthermore, as the 
disease progresses, additional LDL retention mechanisms facilize further LDL 
accumulation. LPL, independently from its enzymatic activity, is able to bind both 
proteoglycans and LDL, and it therefore acts as a physical bridge in the interaction 
LDL-proteoglycans enhancing LDL retention in the artery wall. In established plaques, 
it causes an actual shift in the LDL retention mechanisms from a low-affinity ionic 
interaction LDL-proteoglycans to a high-affinity bridge interaction LDL-LPL-
proteoglycans.63 Increased expression of LDL aggregating enzymes may further 
contribute to accelerated LDL accumulation. Aggregated LDL present increased 
affinity for proteoglycans because of conformational changes that expose additional 
positively charged domains on ApoB and the presence of multiple GAG-binding 
sites.64 Also, because of their large size, LDL aggregates cannot efflux back into the 
bloodstream, contributing to additional LDL entrapment.11  
These shifts in retention mechanisms may explain why lower plasma LDL levels 
appear to be needed for the growth of plaques than for their initiation;11 there is indeed 
a strong correlation between LDL levels during young adulthood and the risk of 
developing atherosclerotic cardiovascular events later in life.1 
 
1.1.6. Atherosclerosis progression 
Xanthomas or fatty streaks, corresponding to intimal accumulation of foam 
cells, are harmless and fully reversible. They can be found already in fetal aortas and 
very young infants (<6 months of age), especially in the case of hypercholesterolemic 
mothers. However, their number usually declines during young life to only reappear at 
atherosclerosis-prone sites during adolescence.65,66 Xanthomas can eventually 
progress to pathological intimal thickening when foam cells start to undergo apoptosis, 
causing accumulation of cell debris and extra-cellular lipid pools. These 
lesions, commonly observed from 20 to 30 years of age at predilection sites, are 
characterized by a conserved structure of the intima but with accumulated lipid 
pools beneath the layers of foam cells.67 Further accumulation of apoptotic cells, 
apoptotic remnants and confluence of isolated lipid pools lead to the formation of a 
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necrosis area known as necrotic core, characterized by little or no presence of cells 
and extracellular matrix. This process irreversibly disrupts the normal structure of the 
intima. Lesions that contain one or more necrotic cores are defined as 
fibroatheromas.67 Fibroatheromas exhibit a characteristic fibrous cap, a layer of 
VSMCs, and collagenous-proteoglycan matrix located towards the luminal surface of 
the plaque. Necrotic cores can accumulate calcium deposits until they are completely 
calcified, giving rise to fibrocalcific plaques.68 Advanced plaques can eventually 
undergo erosion or rupture, causing thrombosis and possibly severe clinical 
manifestations (coronary heart disease, ischemic stroke, or peripheral vascular 
disease). 
 
1.1.7. Why does atherosclerosis initially attack atherosclerosis-prone 
sites? 
The factors that induce atherosclerosis (LDL, hypertension, etc) are all 
systemic; yet atherosclerosis affects the arterial tree very heterogeneously attacking 
mainly low shear-stress regions near branch points and in inner curvatures. Several 
theories have been proposed to explain this, but the relative importance of each of the 
processes described below for determining the topography of atherosclerosis is still 
unsettled.  
According to the mass transport theory of atherosclerosis, the arterial uptake of 
atherogenic material from blood, primarily low-density lipoproteins (LDL), is higher at 
sites of low or disturbed blood flow. This is explained by a combination of increased 
residence time of circulating LDL at sites with low wall shear stress and increased 
endothelial permeability in such areas.69 The theory is supported by studies that show 
increased uptake at atherosclerosis-prone sites of iodinated LDL and Evan’s Blue 
Dye-labeled albumin.70,71 The mass transport theory therefore highlights the 
importance of the rate of LDL entry.   
The response-to-retention theory of atherosclerosis states that the retention 
of LDL to proteoglycans in the intimal layer of the artery wall is the key initiating event 
in lesion development. Altered shear stress has been shown to induce synthesis of 
molecules, including  proteoglycans, that promote intimal matrix remodeling and 
therefore lipoprotein binding.23  Indeed, the introduction of a disturbed blood flow in 
the atherosclerosis-resistant common carotid artery is sufficient to increase lipoprotein 
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retention.72 Also, humans develop spontaneously adaptive intimal thickening at these 
predilection sites after birth. Adaptive intimal thickening is characterized by vascular 
smooth muscle cell accumulation within the intima, which represent the main 
producers of extracellular matrix components.73 In contrast to the mass transport 
theory, the response-to-retention model highlights the importance of retention of the 
delivered atherogenic material. 
The endothelial dysfunction theory of atherosclerosis proposes that low shear 
stress primes for atherosclerosis by changing endothelial function. Shear stress-
induced mechano-transduction mechanisms convert mechanical forces to 
biochemical responses, activating signal transduction and finally gene and protein 
expression that determine endothelial cell phenotype.14 The diverse endothelial cell 
phenotype among high and low sheer stress arterial sites is already appreciated at the 
morphological level. Endothelial cells are fusiform and aligned in the direction of the 
flow in the presence of high sheer stress while they assume a more polygonal shape 
and random orientation as the magnitude reduces.74 At the functional level, in the 
straight part of the arterial tree, the athero-protective role of unidirectional blood flow 
includes an anti-proliferative, anti-apoptotic, anti-oxidant and anti-inflammatory effect 
on endothelial cells.69 In contrast, disturbed blood flow reduces the production of nitric 
oxide,75 increases endothelial turnover,14  and activates pro-inflammatory pathways 
(ie, NF-kB pathway).58 Indeed, low-shear stress regions of the normal arterial 
vasculature exhibit increased expression of chemoattractants and adhesion molecules 
for monocytes that may facilitate LDL-induced inflammation. The endothelial 
dysfunction theory therefore highlights differences in the biological response to 
accumulated LDL.  
 
1.1.8. Previous mapping studies of LDL entry and retention rates 
A logical way to test the merits of these theories in explaining the differences in 
atherosclerosis susceptibility is to measure the dynamics of LDL accumulation. The 
mass transfer theory would predict that atherosclerosis-prone sites correspond to 
regions with high LDL entry. The response-to-retention theory that atherosclerosis-
prone sites are those with higher LDL retention. The endothelial dysfunction theory 
does not presuppose, but also does not exclude, a particular correlation between the 
topography of LDL deposition and atherosclerosis initiation.  
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There is today clear evidence from humans and experimental models that the 
most atherosclerosis-prone sites are those that accumulate more LDL in the arterial 
intima when blood LDL levels are high.39,76 However, uncertainty remains about 
whether this is explained by increased entry or retention.11 Furthermore, the potential 
existence of feedback loops already in early LDL accumulation steps, which may 
facilitate further entry or retention, is incompletely understood. 
Previous studies in this field have relied on radioactive labeling to map LDL 
entry and retention across arteries in animal models, but the results have not been 
consistent. Schwenke and Carew in 1989 found that atherosclerosis-susceptible 
arterial regions in rabbits are characterized by higher LDL retention, but not higher 
LDL entry.39 Yet Nielsen et al. subsequently found higher LDL entry in atherosclerosis-
prone regions in rabbits,70 and no association between increased aortic LDL entry and 
subsequent lesion development was found in pigeons.77 Moreover, studies from the 
70s and 80s in squirrel monkeys and mini-pigs showed higher LDL entry in sites that 
rarely develop atherosclerosis, such as veins and pulmonary arteries, compared to the 
atherosclerosis-prone aorta.78,79 In mice, the relative contribution of LDL entry or 
retention to atherosclerosis initiation has not been well studied, and it still remains 
uncertain whether LDL entry or retention is more characteristic for the atherosclerosis-
prone sites.  
The radioactive techniques used by the majority of previous studies to map LDL 
entry and retention across arteries are quantitative but have low resolution and 
typically measure LDL entry and retention rates as averages over large regions. Most 
of these studies have measured the accumulated radioactivity in the arterial wall after 
an intravenous injection of radiolabeled iodine-LDL (*I-LDL) at different time points.26 
The assessment of *I-LDL concentration requires either micro-sectioning of the arterial 
wall prior to the gamma-counting quantification of aortic radioactivity,26,80 or 
histological cross-sectioning of the arterial wall prior to quantitative autoradiography.78 
Both tissue processing requirements lead to the loss of information on the 
topographical distribution of LDL entry and retention across the arterial tissue. 
Alternatively, autoradiography can be done on en face aortas fixed on a radiographic 
sheet film and apposed on an autoradiography intensifying screen, allowing higher 
information on the topographical distribution of radiolabeled LDL but with low 
resolution.81 These limitations are a tangible shortcoming because atherogenesis is 
initially a microscopic phenomenon with sites of incipient atherogenesis and normal 
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arterial wall separated by short distances. To understand how rates of LDL entry and 
retention may determine the susceptibility of the arterial wall to atherosclerosis, further 
investigation of these processes is needed with techniques that allow higher spatial 
resolution.   
 
 
1.2. Animal models of atherosclerosis  
Measuring the rates of LDL entry and retention in human arteries before and 
during atherosclerosis initiation is very difficult if not downright impossible. For that 
reason, previous studies and the present thesis rely on the use of 
hypercholesterolemic animals to model the onset of atherogenesis.  
Many of these types of models have been developed over the last century. In 
1908, Ignatowski was the first to induce atherosclerosis in an animal species by 
feeding rabbits a diet enriched in animal proteins (milk, meat, and eggs).8 Since then 
many other species such as mice, rats, guinea pigs, hamsters, birds, pigs, and non-
human primates have been used as experimental models of atherosclerosis.10 Over 
the past decades, murine models became the most commonly used to study 
experimental atherosclerosis because of low cost, rapid reproduction, ease of genetic 
manipulation and the possibility to evaluate atherogenesis in a relatively short time 
frame. Although the mouse today is the organism in which the mechanisms of 
atherosclerosis are best understood, the dynamics of LDL entry and retention have 
not yet been comprehensibly mapped. The next sections will briefly review the mouse 
as a model for atherosclerosis and the tools that are available to alter the levels of LDL 
and other ApoB-containing lipoproteins in them. 
 
1.2.1. Lipid metabolism 
Mice are “HDL” animals (i.e. HDL is the primary lipoprotein) and they present 
very low circulating LDL levels. They are therefore relatively resistant to the 
development of atherosclerosis, even with high-fat feeding. For this reason, mice 
require genetic manipulation of lipid metabolism genes to develop severe 
hypercholesterolemia.82,83  
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Lipid metabolism relies on plasma lipoproteins that allow transport of dietary 
lipids from the small intestine to peripheral tissues, the transport of endogenous lipids 
from the liver to peripheral tissues, and the transport of lipids from peripheral tissues 
to liver and intestine (reverse cholesterol transport) (Figure 4).84 Lipoproteins can be 
divided according to their density in chylomicrons, chylomicron remnants, very low-
density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density 




Figure 4. Lipid metabolism and transport. Schematic representation showing the transport of dietary 
lipids from the small intestine to peripheral tissues, the transport of endogenous lipids from the liver to 
peripheral tissues, and the transport of lipids from peripheral tissues to liver (reverse cholesterol 
transport). Details are described in the main text. 
Chylomicrons (size, 80-500 nm, density, <0.95 g/ml) transport dietary 
triglycerides and cholesterol to peripheral tissues from the small intestine (exogenous 
pathway). These particles contain the short form of ApoB (ApoB48), created by ApoB 
mRNA editing enzyme catalytic polypeptide 1 (APOBEC1) editing of the ApoB mRNA, 
ApoA-I, ApoA-II and ApoA-IV. In the circulation, nascent chylomicrons acquire ApoC-
II and ApoE from HDL. Lipoprotein lipases (LPL) located in the capillaries of peripheral 
tissues, mainly adipose and muscle tissues, are activated by ApoC-II and hydrolyze 
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triglycerides into fatty acids. As the tissues absorb the fatty acids, chylomicrons shrink 
to the more pro-atherogenic chylomicron remnants (size, 50 nm; density, 1.006 g/ml), 
which are cleared from the circulation by both hepatic LDLR and LDLR-related protein 
1 (LRP1) through binding to ApoE.84–86  
VLDLs (size, 30-80 nm; density, 0.95-1.006 g/ml) transport endogenous 
triglycerides and cholesterol to peripheral tissues from the liver (endogenous 
pathway). The liver secretes VLDL via exocytosis. Nascent VLDLs contain ApoB100 
in humans and acquire ApoC-II and ApoE from HDL once entered into the circulation. 
In mice, approximately half of the secreted VLDL contain ApoB48 because of some 
hepatic activity of the APOBEC1 enzyme.87 As for chylomicrons, lipoprotein lipases 
located in the capillaries of peripheral tissues hydrolyze triglycerides into fatty acids. 
The absorption of fatty acids by the tissues and the transfer of ApoC-II and 
phospholipids back to HDL convert VLDL to the more pro-atherogenic IDL (size, 25-
35 nm; density, 1.006-1-019 g/ml), containing ApoB-100 or ApoB-48 and ApoE. IDL 
can be cleared from the circulation through LDLR/LRP1 hepatic binding or be further 
catabolized by lipoprotein lipases, eventually losing ApoE to form LDL (size, 18-28 
nm; density, 1.019-1.063 g/ml).85,88  
In humans, LDL are the main plasma cholesterol carriers that deliver cholesterol 
to cholesterol-requiring tissues. LDLs that are not taken up in the periphery are 
predominantly cleared by the hepatic LDLR that binds ApoB100 and internalizes the 
LDL/LDLR complex by endocytosis into clathrin-coated vesicles. The internalized 
particles are routed to endosomes, where LDL dissociates from LDLR because of the 
low pH in the endosomal lumen. Dissociated LDL is transferred to late endosomes 
and lysosomes, where the particle is finally digested, and the cholesterol and 
triglycerides are de-esterified for transport into the cytosol. On the contrary, the LDLR 
is recycled back to the hepatocyte surface to participate in more rounds of LDL binding 
and endocytosis.89 ApoB-48-LDL in mice lack the LDLR-binding site, however they 
accommodate a large amount of ApoE that allows clearance through both hepatic 
receptors, LDLR and LRP1.87  
HDL (size, 7-12 nm; density 1.063-1.210 g/mL) are involved in reverse 
cholesterol transport, i.e. the transport of cholesterol excess from peripheral tissues to 
the liver for metabolism into bile salts.90 Intestine and liver synthesize the protein 
ApoA-I that is secreted in the bloodstream in a lipid-free state.91 In peripheral tissues, 
ATP-binding cassette sub-family A member 1 transporter (ABCA1) mediates the efflux 
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of phospholipids and free cholesterol on ApoA-I resulting in the generation of a 
“nascent” HDL particle. The latter then interacts with SR-B1 and ATP-binding cassette 
sub-family G member 1 transporter (ABCG1) on peripheral cells to further incorporate 
cholesterol, forming a mature HDL particle. HDLs interact with SR-B1 in the liver, 
which allows the transfer of its cholesterol content.92,93 
 
1.2.2. Mouse models of atherosclerosis 
The two most frequently used mouse models of atherosclerosis are the Apoe 
knockout (Apoe−/−) model and the Ldlr knockout (Ldlr−/−) model.  
Apoe−/− mice were developed in 1992 and were the first mouse genetic model 
of atherosclerosis to be created.94 ApoE is a ligand for LDLR and LRP1, and the lack 
of ApoE respectively reduces and totally blocks the clearance of ApoB-containing 
lipoproteins through these receptors causing massive accumulation of VLDL and 
chylomicron remnants.95 These mice therefore develop atherosclerotic lesions even 
when fed normal low-fat chow diet.95 The severity of the phenotype can be further 
accentuated by feeding a high fat, high cholesterol Western type diet (WTD) (typically 
0.2% cholesterol, 21% milkfat).96 Apoe−/− mice represent a very useful tool to study 
atherosclerosis; however plasma cholesterol is mostly carried on chylomicron and 
VLDL remnants rather than LDL, which is the most frequent pro-atherogenic particle 
in human atherosclerosis. Also, ApoE has non-lipid-related functions in immune 
responses and adipose tissue biology,97 which may impact atherosclerosis directly.  
Ldlr−/− mice were developed in 1993.98 In this model, the clearance of 
lipoproteins through the LDLR is blocked, resulting in moderate accumulations of LDL 
on normal chow diet and severe hypercholesterolemia on a high-fat diet.98 The milder 
phenotype of the Ldlr−/− mouse is unlike humans, where mutations in LDLR yield 
higher plasma cholesterol levels than mutations in the APOE gene. The milder 
phenotype of LDLR deficiency in mice is related to their hepatic secretion of ApoB48-
VLDLs, which is absent in humans. The higher ratios of ApoB48 to ApoB100-
containing lipoproteins in plasma decrease the relative importance of LDLR-ApoB100-
mediated versus LDLR/LRP1-ApoE-mediated clearance.87 The advantage of the 
Ldlr−/− model is that LDLR does not appear to exert a multitude of extra-hepatic 
functions as described for ApoE.99 Also, this model has a lipoprotein profile that is 
more similar to humans with LDL as the main cholesterol-carrying plasma 
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lipoprotein.99 Furthermore, Ldlr−/− mice mimic the phenotypic events described in 
human familial hypercholesterolemia caused by homozygous null mutations in the 
LDLR gene, which is much more common than familial dysbetalipoproteinemia caused 
by homozygous null mutations in the APOE gene.100 
Today experimental atherosclerosis research strongly relies on Apoe−/− and 
Ldlr−/− models, however, in these mice the hypercholesterolemia phenotype is inborn 
and the exact time point of initiation of atherosclerosis is therefore not well-defined. 
More control over the timing of LDL increase can be achieved with virus-mediated 
gene transfer models, such as the ones obtained though the rAAV-PCSK9 technique.  
PCSK9 is a serine protease present in plasma and highly expressed in the 
liver.101 After protein maturation and secretion, circulating PCSK9 binds hepatic LDLR 
and targets them to lysosomal degradation, diverting the receptor away from the 
normal recycling to the hepatocyte surface that follows internalization of the LDLR/LDL 




Thus, hyperactivity of PCSK9 reduces the density of LDLR on the surface of 
hepatocytes, resulting in reduced LDL clearance and raised circulating LDL levels. 
Clinical studies have shown that PCSK9 gain-of-function mutations are associated 
with severe familial hypercholesterolemia and premature CVD.103 On the other hand, 
Figure 5. PCSK9-mediated LDLR degradation. 
Secreted PCSK9 binds to LDLR on the 
hepatocyte surface and promotes the lysosomal 
degradation of the PCSK9-LDLR-LDL complex, 
reducing the total number of LDLR involved in 
hepatic LDL clearance. 
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loss of function mutations in PCSK9 lead to lower plasma levels of LDL and protection 
from CVD.104 Mice expressing a gain-of-function mutant of PCSK9 delivered by 
recombinant adeno-associated virus (rAAV) and fed a high fat diet develop sustained 
hypercholesterolemia and atherosclerosis.105,106 Indeed, rAAV-PCSK9-induced mice 
develop a phenotype similar to that of Ldlr−/− mice. This method presents the 
advantage of allowing a prompt induction of high LDL levels and atherosclerosis in 
normal mice at the time point of choice.105 This permits more systematic studies of the 
relationships between the entry, retention and accumulation of LDL, and the onset of 
atherogenesis than is possible with Apoe−/− and Ldlr−/− mice.  
Overall, mouse models are powerful tools to improve the understanding of the 
molecular mechanisms behind atherosclerosis susceptibility, initiation, and 
progression, but they also present some differences with the human disease. As in 
humans, lesions in mice start with foam cell formation in regions of disturbed blood 
flow with predilection sites in the aortic root, the inner curvature of the aortic arch, the 
brachiocephalic trunk, the abdominal aorta, and the branch points of the left carotid 
and subclavian arteries.100,107 Mice may also develop some atherosclerosis in the 
proximal parts of the coronary arteries, but this appears to be an extension of aortic 
root lesions rather than isolated lesions initiated in the coronaries as is generally the 
case for coronary artery disease in humans.100 Also, while intimal thickening with 
VSMCs accumulation in the intima usually occurs in early lesions in humans, this is 
not the case in mice that exhibit a very thin intima consisting only of endothelium and 
scattered dendritic cells.108 
 
1.2.3. Tools to lower LDL levels in mice 
In addition to tools that can increase LDL and cause atherosclerosis, there are 
several available tools for reducing LDL levels. Many investigators have used them to 
study the changes in plaque biology that occur when atherosclerotic patients are 
treated with cholesterol-reducing medications that reduce the incidence of 
cardiovascular events.109 Cholesterol-lowering drugs for use in humans include, 
among others: statins, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase 
inhibitors that block the pathway for synthesizing cholesterol in the liver and increase 
LDLR levels, thereby reducing LDL plasma levels by as much as 60%;110 ezetimibe, 
an intestine cholesterol absorption inhibitor that reduces delivery of cholesterol to the 
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liver, thereby reducing LDL plasma levels by 20%;110 and PCSK9 inhibitors, 
monoclonal antibodies that lower LDL plasma levels by 50-60% by binding PCSK9, 
which in turn decreases the degradation of LDL receptors.110 
For studies in mice, alternative tools are available that allow correction of the 
severe hypercholesterolemia of atherosclerosis models.111 An indirect model was 
developed in 2001112 in which atherosclerotic aortas are transplanted from donor mice 
with high plasma LDL levels into healthy recipient mice with low plasma LDL levels.112 
Other important models are based on the genetic deletion113 or pharmacological 
inhibition114 of the microsomal triglyceride transfer protein (MTP), required for the 
proper packaging of VLDL and chylomicrons in intestine and liver. Both tools induce 
rapid reduction in chylomicrons remnants and LDL levels.113,114 Furthermore, 
normalization of plasma cholesterol levels has been achieved through adenovirus-
mediated re-introduction of the Apoe and Ldlr genes in Apoe−/− and Ldlr−/− mice, 
respectively, combined with switching to low-fat chow diet.115,116 Finally, in recent 
years, the use of antisense oligonucleotides (ASOs) against the ApoB mRNA has 
been implemented as a very convenient and efficient tool to reduce LDL plasma levels. 
Weekly injections of antisense oligonucleotides targeting Apolipoprotein B (ApoB 
ASO) can reduce hepatic ApoB mRNA expression by 90% and consequently lower 




Figure 6. Effect of ApoB ASO treatment. The ApoB ASO targets the hepatic ApoB mRNA thereby 
reducing the hepatic output of VLDL, which in turn causes a drastic reduction in LDL plasma levels. 
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The processes controlling LDL accumulation and atherosclerosis onset at 
atherosclerosis-prone sites of the vasculature remain incompletely understood. We 
hypothesized that the use of high-resolution LDL tracking techniques in mice with 
control of LDL levels would provide new insights into the processes that drive LDL 
accumulation at some sites while protecting against it at other sites.  
 
To explore this idea, we set the following objectives: 
 
1. To study the temporal relationship between LDL accumulation and onset of 
atherogenesis in the mouse aorta. 
 
2. To develop techniques that allow mapping of the rates of LDL entry and 
retention at microscopic resolution in the mouse aortic arch. 
 
3. To evaluate whether rates of LDL entry and/or retention are changed in pre-
atherosclerotic arteries compared with normal arteries and how they vary 
during the first weeks after the onset of hypercholesterolemia. 
 
4. To analyze the topographical distribution of LDL entry and retention across 
the mouse aortic arch in normal and pre-atherosclerotic arteries and how this 
correlates with the sites of atherosclerosis initiation. 
 
5. To assess whether LDL retention rates change in lesioned arteries compared 























































































3.1. LDL labeling and infusion 
Blood for LDL isolation was collected in EDTA-coated tubes from healthy 
volunteers after informed consent, as approved by the Comité de Ética de la 
Investigación del Instituto de Salud Carlos III (CEI PI 12_2016-v2). Plasma was 
isolated by centrifugation and mixed with KBr to a density of 1.21 g/l and layered in a 
KBr density gradient column (density layers: 1.006, 1.019, 1.063, and 1.21 g/ml; Tube, 
Thinwall Ultra Clear, Beckman Coulter). The column was ultracentrifuged at 40,000 
rpm (Beckman Coulter Optima L- 100K Ultracentrifuge, SW 40 Ti Rotor) and 4°C for 
20 hours. Human LDL was collected from the 1.063 g/ml density layer and 
concentrated using the Amicon system (Amicon Ultra-15, membrane PLTK Ultracel-
PL, 30 kDa) at 4,000 rpm (Eppendorf Centrifuge 5810, A-4-81 Rotor) and 4°C until 
volume reduction to approximately 2.5 mL. LDLs were then purified on a PD10 
desalting column (GE Healthcare) with PBS and quantified using the BCA protein 
assay kit (ThermoFisher). For en face experiments, the human LDLs were conjugated 
at a 1:2 molar ratio to Atto680 N-hydroxysuccinimide (NHS) ester fluorochrome (Sigma 
Aldrich) at pH 8.3, with 0.1 M NaHCO3 following the manufacturer’s protocol; for 
confocal microscopy experiments, conjugation was to either Atto565 or 647 NHS ester 
fluorochrome (Sigma Aldrich). The Atto NHS labels attach to free amines on the 
protein moiety of LDL, Apolipoprotein B. Human labeled LDLs were then purified on a 
PD10 column with PBS to remove excess fluorochrome and quantified again using the 
BCA protein assay kit (ThermoFisher). 
 
 
3.2. Animal procedures 
Animal experiments were approved by the ethical review boards at CNIC and 
Universidad Autónoma and approved by the Comunidad de Madrid (PROEX 266/16). 
The mice used in this study were male Ldlr (Low-density lipoprotein receptor) knockout 
mice (B6.129S7-Ldlrtm1Her/J, Jackson Laboratory) and male wild-type B6 mice 
(C57BL/6J, Jackson Laboratory). All compared mice were littermates, housed 






3.2.1. Fluorescently labeled human LDL injections 
To measure rates of LDL entry and retention, mice were infused through the 
tail vein with fluorescently labeled human LDL followed by sacrifice after 1 hour (to 
measure rate of LDL entry) or 18 hours (to measure rate of LDL retention). In single-
label experiments, i.e. when evaluating LDL entry and LDL retention between different 
samples, mice were injected either at 18 hours or 1 hour before the endpoint with 500 
μg of human LDL conjugated with either Atto680, Atto647 or Atto565 diluted in PBS. 
In double-label experiments, i.e. when evaluating the pattern of LDL entry and LDL 
retention in the same sample, mice were injected at 18 hours and 1 hour before the 
endpoint with 250 μg of human LDL conjugated with different fluorophores (Atto647 or 
Atto565).  
To evaluate the proportionality between the Atto680-LDL infrared signal 
detected in arteries and the amount of labeled LDL injected, mice were injected with 
unlabeled LDL alone (500 μg of unlabeled LDL), a mix of unlabeled and labeled LDL 
with increasing percentages of labeled LDL (375 μg unlabeled LDL+ 125 μg labeled 
LDL; 250 μg unlabeled LDL+ 250 μg labeled LDL; 125 μg unlabeled LDL+ 375 μg 
labeled LDL) or labeled LDL alone (500 μg of labeled LDL). Plasma concentrations of 
infused labeled LDL were determined in blood samples using a FluoriskanAscent 
fluorometer (Thermo Labsystems).  
 
3.2.2. Tools to control LDL levels 
LDL levels were increased using a single tail vein injection of recombinant 
adeno-associated virus encoding a D377Y gain-of-function mutant of PCSK9 (rAAV-
PCSK9). rAAV-PCSK9-mediated gene transfer leads to high hepatic expression of 
D377Y-PCSK9 resulting in persistent downregulation of LDL receptors as previously 
described.105 Control rAAV8 virus particles without the PCSK9 encoding cassette were 
used as control (rAAV-control). The pAAV/D377Y-mPCSK9 plasmid used to create 
rAAV-PCSK9 particles is composed of an ampicillin resistance cassette, left and right 
inverted terminal repeats (ITR), a liver-specific promoter (ApoEHCR-hAAT) consisting 
of the hepatocyte control region (HCR) from the APOE gene and the human α1-
antitrypsin promoter (hAAT) promoter, the D377Y-mPCSK9 cassette encoding gain-




signal (BGHpA). The pAAV/control plasmid used to create rAAV-control particles has 




Figure 7. Plasmid maps. A, pAAV/D377Y-mPCSK9 (6519 bp) and B, pAAV/control (4443 bp). 
Following transformation and amplification in Ca+2 competent E. coli H5 
bacteria, pAAV-D377Y-mPCSK9 and pAAV-control were purified using the QIAGEN 
Maxi Plasmid Purification Kit, following manufacturer's instructions. After digestion 
with the restriction enzymes AhdI and BglI to verify the integrity of the terminal inverted 
repeats (ITR), the viral vector particles were produced by the CNIC viral vector core 
facility. For the tail vein injection, 1 × 1011 viral particles were diluted in 200 μl of NaCl 
and injected in mice previously kept in a warming chamber to induce vasodilation. 
Approximately 6 hours after injection, mice were put on high-cholesterol diet (S9167-
E011, Sniff) or kept on standard laboratory chow diet, according to the aim of the 
individual experiments. Blood samples for LDL cholesterol and other measures were 
drawn before viral vector injection and at different time points following injection, 
depending on the experiment.  
LDL levels were decreased using the 14-mer locked nucleic acid (LNA) 
antisense oligonucleotide targeting ApoB mRNA (ApoB ASO, 5’-3’: 
AGmCattggtatTmCA, where the uppercase letters indicate LNA monomers, lowercase 
letters indicate DNA monomers, and mC stands for LNA-5-methylcytidine) (Exiqon).119 
The ASO was administered either weekly (5mg/kg) or in a single high dose (10mg/kg), 
according to the aim of the individual experiments. The same dose of a standard 15-
mer LNA negative control antisense oligonucleotide without homology to any known 




aacacgtctatacgc, the position of the LNAs is proprietary information not revealed by 
Exiqon).  
Using the tools to increase and/or decrease plasma LDL levels, the following 
types of experiments were done (group sizes and further details are discussed in the 
results section):  
• To evaluate the progression in LDL accumulation after the onset of 
hypercholesterolemia, mice were injected with rAAV-PCSK9 (8 weeks of age) 
and subsequently kept on high-cholesterol diet for 2, 4, 6, or 12 weeks.  
• To rule out a direct effect of PCSK9 on LDL entry and retention in arteries, 
Ldlr -/- mice (8 weeks of age) fed standard laboratory chow diet received a 
tail vein injection of rAAV-PCSK9 or rAAV-control virus particles and were 
sacrificed after 3.5 weeks. 
• To create groups of mice that differ in plasma LDL levels without differences 
in hepatic LDL clearance, all mice (8 weeks of age) received a tail vein 
injection of rAAV-PCSK9 to reduce hepatic LDL clearance and were fed 
high-cholesterol diet for 3.5w. Some mice (normocholesterolemic group with 
normal arteries) were concomitantly treated weekly with a dose of 5mg/kg of 
Apob ASO to keep LDL at normal levels (by reducing hepatic VLDL output), 
while others (hypercholesterolemic group with pre-atherosclerotic arteries) 
received the same dose of Ctrl ASO. The two groups were compared for 
rates of entry and retention of labeled LDL and for arterial gene expression. 
• To measure LDL entry and retention rates during the first weeks after the 
onset of hypercholesterolemia, mice received a tail vein injection of rAAV-
PCSK9 and were started on high-cholesterol diet at 8, 10, or 11 weeks of 
age. After 4, 2, or 1 weeks of hypercholesterolemia, respectively, rates of 
LDL entry and retention were measured. This design allowed the use of the 
same labeled LDL preparation for all groups enabling comparison without 
potential bias caused by differences in LDL preparation or labeling. 
• To assess the rate of labeled LDL retention shortly after the induction of 
hypercholesterolemia, two groups of mice (8 weeks of age) received a tail 
vein injection of rAAV-PCSK9 and were started on high-cholesterol diet. One 




other group received a similar dose of Ctrl ASO. Mice were sacrificed after 3 
days. 
• To evaluate the effect of rapid LDL lowering on the rate of labeled LDL 
retention, two groups of mice (8 weeks of age) received a tail vein injection 
of rAAV-PCSK9 and were kept on high-cholesterol diet for 3.5w. At 3 days 
before the endpoint, the groups received a single 10mg/kg dose of either 
ApoB ASO or Ctrl ASO. 
• To analyze the topography of atherosclerotic lesions at different time points 
after the induction of hypercholesterolemia, mice (8 weeks of age) received 
a tail vein injection of rAAV-PCSK9 and were kept on high-cholesterol diet 
for 4w, 6w, 12w, and 24w. 
• To study the rate of labeled LDL retention in atherosclerotic arteries, mice (8 
weeks of age) received a tail vein injection of rAAV-PCSK9 and were kept 
on high-cholesterol diet for 12w. At 1 week before the endpoint, one group 
of mice received a single 10mg/kg dose of ApoB ASO to abruptly lower LDL 
levels, while the others received a similar dose of Ctrl ASO. 
 
3.2.3. Endpoint procedure 
Mice were sacrificed by intraperitoneal injection of pentobarbital (250 mg/kg) 
and lidocaine (20 mg/kg). After sacrifice, mice were exsanguinated and perfused first 
with KCl solution (50 mM, 30 seconds) and then with 4% phosphate-buffered 
formaldehyde (5 minutes) at approximately 100 mmHg through the left ventricle, using 
the cut right atrium as the drainage route. Mice were then immersion-fixed in 4% 
phosphate-buffered formaldehyde for a further 18 hours, followed by storage in PBS 
at 4°C until extraction of the aorta and heart.  
Only in the case of sample preparation for RNA sequencing of the inner 
curvature region of the aortic arch, a different procedure was followed. Mice were 
euthanized as detailed above but perfused with ice-cold PBS (5 minutes), and aorta 
extraction and separation of the inner aortic curvature region were performed 
immediately. Inner aortic curvature samples were then quickly snap-frozen in liquid 





3.3. Tissue processing 
For the analysis of cross-sections of the ascending aorta and aortic root, the 
aorta and heart were extracted from perfusion-fixed mice and the aortic arch was 
separated from the heart. Both tissues were cryoprotected (24 hours in 25% sucrose 
w/w followed by 24 hours in 50% w/w sucrose in phosphate-buffered saline [PBS]). 
Tissues were then embedded in Tissue-Tek O.C.T. Compound (Sakura) and snap-
frozen in liquid nitrogen. The ascending aorta was sectioned (5 μm) from the proximal 
end until the branch point of the brachiocephalic trunk. Cross-sections of the aortic 
root (5 μm) were obtained from the commissures of the aortic cusps upwards.  
In mice not injected with labeled human LDL, LDL accumulation was quantified 
by staining for ApoB in the ascending aorta and aortic root sections (at three positions 
for each mouse, separated by 200 µm and 100 µm in the two locations, respectively). 
After antigen retrieval in 0.05% trypsin solution, sections were stained with goat 
polyclonal anti-ApoB antibody (dilution 1:300, ab98132, Abcam, UK), which 
recognizes mouse ApoB, followed by HRP-coupled secondary antibody (dilution 
1:500, A15999, ThermoFisher) and DAB staining.  
In mice injected with labeled human LDL, labeled LDL was detected in 
ascending aorta sections by its fluorescence and macrophages by staining with rat 
Anti-Mac-2 (Galectin-3) antibody (dilution 1:100, CL8942AP, CEDARLANE) followed 
by Alexa Fluor 568 Goat Anti-Rat IgG (H+L) (dilution 1:500, A-11077, Invitrogen). 
Three levels for each mouse, separated by 200 µm, were analyzed by confocal 
microscopy (Zeiss LSM780 confocal microscope or Leica SP8 Lightning-Navigator 
confocal microscope). Specificity was evaluated by observing the expected 
localization pattern and with negative controls without labeled LDL injection or omitting 
the anti-Mac-2 primary antibody.  
For en face imaging scans of aortas from Atto680-LDL-injected mice, extracted 
aortas from perfusion-fixed mice were opened longitudinally along the outer and inner 
curvature and along the front of the descending aorta and mounted on microscope 
slides using SlowFade™ Gold Antifade Mountant (S36937, ThermoFisher) and 
coverslips. Microscope slides were scanned using the 700 nm channel of a LiCor 
Odyssey Infrared Imaging System. Aortas from mice not infused with labeled human 




For whole-mount confocal microscopy of ascending aortic arches from mice 
injected with both Atto647-LDL and Atto565-LDL, aortas were extracted from 
perfusion-fixed mice, and the ascending aortic arch until the brachiocephalic trunk was 
separated from the rest of the vessel. The ascending aortic arch was opened up to the 
brachiocephalic trunk along the ventral wall to maintain the atherosclerosis-prone 
inner curvature region intact. Samples were mounted on microscope slides in 
SlowFade™ Gold Antifade Mountant, and images of green autofluorescence, Atto565, 
and Atto647 fluorescence were acquired with a Zeiss LSM 780 confocal microscope 
or Leica SP8 Lightning-Navigator confocal microscope. For detection of macrophages 
in whole-mount preparations of ascending aorta, the specimens were first 
permeabilized/blocked with PBS containing 0.5% Triton X-100 and 20% chicken 
serum and then further blocked with PBS containing 0.3% Triton X-100, 5% bovine 
serum albumin, and 5% chicken serum. Aortas were then stained overnight with rat 
anti-Mac2 antibody (dilution 1:100, CL8942AP, CEDARLANE), followed by Alexa 
Fluor 488 Chicken anti-Rat IgG (H+L) (dilution 1:100, A-21470, ThermoFisher). Mac2 
staining was performed as a post-staining in specimens already analyzed for Atto647-
LDL and Atto565-LDL presence.  
For the assessment of the topography of atherosclerotic lesions across the 
ascending aortic arch, aortas were extracted from previously fixed mice and opened 
as described above. En face images were acquired using a Nikon stereomicroscope. 
 
 
3.4. Image analysis 
All quantitative image analysis was performed in Fiji (Fiji is just ImageJ)120,121 
version 2.0.0-rc-69/1.53c and associated plugins122,123 with the contribution of the 
microscopy unit of CNIC.  
 
3.4.1. Quantification of ApoB in serial cross sections 
The analysis of DAB signal in color images of ascending aorta and aortic root 
sections stained for ApoB was performed using the Colour Deconvolution Plugin with 
the provided “H DAB” vector.122 After color separation, regions of interest (ROIs) 
corresponding to total tissue and plaque were defined manually, and areas were 




area of DAB signal within the total tissue ROI was measured (Figure 8). In the aortic 
root, the signal in the three coronary sinuses (left, right, and non-coronary sinus) were 




Figure 8. ApoB staining analysis in sections of ascending aorta and aortic root. A, Workflow used 
in Fiji for DAB quantification in ApoB-stained ascending aorta sections. A representative image of a 
section from a pre-atherosclerotic ascending aorta obtained during the analysis workflow is shown in 
the overview and insets at higher magnification. Tissue ROI and detected DAB is lined by magenta and 
red, respectively. Colour Deconvolution “H DAB” shows the color vectors used for color deconvolution. 
Scale bars, 100 µm in overview and 50 µm in insets. B, Workflow used for aortic root sections. 
Representative images obtained during analysis workflow: an overview of an atherosclerotic aortic root 
section with a marked region in the left coronary sinus, and a higher magnification of the marked region 
showing the tissue ROI (cyan), plaque ROI (magenta), and detected DAB (red). Scale bars, 200 µm in 





3.4.2. Quantification of amount and localization of labeled LDL in en face 
aortic scans 
For measurements of the total quantity of Atto680–labeled human LDLs in 
aortic arches, images from the LiCor Odyssey Infrared Imaging System were 
converted to 8 bit and inverted. The Atto680-LDL positive areas were quantified using 
pixel threshold segmentation within a user defined ROI (including aortic branches and 




Figure 9. Analysis of Atto680-LDL in en face thoracic aorta scans. Workflow used in Fiji for 
measuring the area with Atto680-LDL. Representative images obtained during the analysis workflow. 
The top image shows the inverted image with the gray Atto680 signal. The bottom image shows the 
pixel threshold segmentation selection of the Atto680-LDL positive area (red) and the user-defined ROI 
(yellow perimeter). Scale bars, 1 mm. 
En face images were further analyzed to map potential differences in the 
localization of Atto680-LDL between conditions. To this end, an intensity profile was 
measured along a transverse line (width 3 pixels = 54.54 µm) running from the inner 




transverse line was divided into three zones: central inner (CZ, 0-500 µm), border (BZ 
500-1000 µm), and outer (OZ >1000 µm) zone. A broader range was used for defining 
the border zone than for whole-mount confocal (see below) to account for variability in 
the placement of the longitudinal cut in the central inner zone used to open the aortic 
arch for en face scanning. The analysis was always performed on the dorsal part 
(shown to the left in en face images) of the split ascending aortic arch.  
 
3.4.3. Quantification of amount and localization of labeled LDL and 
macrophages in whole-mount confocal images of the ascending aorta  
The analysis of whole-mount confocal microscopy images was focused only on 
the inner curvature region of the ascending aortic arch. A transverse thick line (width 
200 pixels = 83 µm, length 2000 µm) was placed across the inner curvature region 
and was further divided into three zones: dorsal border zone (BZ1, -1000 – -650 µm), 
central inner zone (CZ, -650 – +650 µm), and ventral border zone (BZ2 +650 – +1000 
µm), with the coordinates referring to the midline of the inner curvature. Negative 
values correspond to the dorsal side of the ascending aortic arch and positive values 
to the ventral side. 
For intensity profile analysis, the signal in z sections was summed using the 
sum slices z-projection method on images after applying background correction, and 
then an intensity profile of Atto647 or Atto565 signal was plotted along the thick line 
area.  
For the co-localization analysis of areas with high LDL entry and areas with high 
LDL retention, and of high-content macrophage and high LDL retention areas, 
individual images with LDL entry/retention and Mac-2 stainings were subjected to sum 
slices z-projection. Because the LDL and Mac-2 signals were captured in separated 
sessions, the sum projected images were rotated using the BigWarp plugin which 
allows the matching of tissue shapes using different landmarks as reference, thereby 
allowing the alignment of separated images of the same specimen.123 After the 
alignment, a straightened new multichannel image containing LDL (entry and 
retention) and Mac-2 signals was created and used for further analysis. Labeled LDL 
(Atto647 or Atto565) and Mac-2 (Alexa488) channels were background corrected and 
their brightness enhanced before pixel thresholding segmentation. Binary mask 




(Atto647 or Atto565), and their individual and co-localization areas were measured. 
To analyze macrophage accumulation in high LDL retention areas, the area occupied 
by LDL retention signal was computed for Mac-2 high-content and Mac-2 low-content 




Figure 10. Co-localization analysis of LDL entry/retention areas and LDL retention in high and 
low content macrophage areas. Left panel, workflow used in Fiji for LDL entry/retention co-localization 
area and LDL retention in Mac-2 high and low areas measurement. Right panel, representative images 
obtained during analysis workflow: top, whole-mount image of part of intact inner curvature region of 
the aortic arch showing LDL entry (red), retention (cyan), and co-localization (white) masks used for 
quantification. Bottom, whole-mount image of part of intact inner curvature region of the aortic arch 
showing LDL retention (gray), Mac-2 staining (green), and corresponding Mac-2 high selection (green 
line) used for quantification. Scale bars, 100 µm. 
 
3.4.4. Quantification of LDL retention and macrophage content in sections 
from ascending atherosclerotic aorta  
To measure the content of retained labeled LDL (Atto647 signal) and of Mac2-
stained macrophages (Alexa Fluor 568 signal) in serial sections of atherosclerotic 
ascending aorta, signals in the confocal z slices were summed and ROIs 
corresponding to tissue and plaque were defined, and their areas quantified. Elastin 
autofluorescence signal was detected and subtracted from the Atto647 channel, and 




were outlined and measured through pixel thresholding segmentation in the plaque 




Figure 11. LDL retention and macrophage content analysis in atherosclerotic aortas. Workflow 
used in Fiji for measurement of areas with LDL retention and macrophages in atherosclerotic ascending 
aortas. Representative images obtained during analysis workflow are shown. The top image shows an 
aortic cross section with LDL retention (gray) and Mac-2 staining (red). The bottom image shows the 
user-defined plaque ROI (light green line), and the detected macrophage (pink line) and labeled-LDL 
(light gray line) ROIs after pixel segmentation thresholding. Scale bars, 30 µm. 
 
 
3.5. Arterial gene expression profiling by RNA sequencing 
Total RNA was isolated from the atherosclerosis-prone inner curvature region 
of pre-atherosclerotic and normal aortic arches using the RNeasy Micro Kit (QIAGEN). 
Tissue disruption and homogenization was performed with TissueRuptor and RNA 
was treated with DNase I according to the manufacturer's instructions. In each group, 
RNA from n=9 mice was pooled in 3 RNA pools of n=3 mice each. RNA quality and 
quantity were evaluated through Agilent Bioanalyzer 2100 using the RNA 6000 Nano 




service was performed by the Genomic Unit of CNIC. Briefly, barcoded RNA-seq 
libraries were prepared using the NEBNext Ultra II Directional RNA Library preparation 
kit (New England Biolabs) according to manufacturer’s instructions. The size of the 
libraries was checked using the Agilent 2100 Bioanalyzer and the concentration was 
determined using the Qubit® fluorometer (Life Technologies). Libraries were then 
sequenced on a HiSeq2500 (Illumina) to generate 60 bases single reads. RNA-seq 
data analysis was performed by the Bioinformatics Unit of CNIC. Briefly, sequencing 
reads were processed with a pipeline that used FastQC to evaluate their quality and 
Cutadapt to trim sequencing reads, eliminating Illumina adaptor remains, and to 
discard reads that were shorter than 30 bp.124,125 Resulting reads were mapped 
against mouse transcriptome GRCm38.91, and gene expression levels were 
estimated with RSEM.126 Around 80% of the reads participated in at least one reported 
alignment. Expected expression count matrices were then processed with an analysis 
pipeline that used Bioconductor package limma for normalization (using TMM method) 
and differential expression testing.127 Changes in gene expression were considered 
significant if associated with Benjamini and Hochberg adjusted p-value < 0.05. 117 
genes were detected as differentially expressed in the performed contrast. An 
Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) was 
performed to interpret the differentially expressed data and identify the most significant 





Statistical tests were performed in Prism 8 (GraphPad Software). Two-sample 
comparisons were analyzed by the unpaired Student’s t-test for normally distributed 
data and by the Mann-Whitney test for non-normally distributed data. Three or more-
samples comparisons were performed with the ANOVA test for normally distributed 
data and by the Kruskal-Wallis test for non-normally distributed data. Post-tests were 
used to interrogate differences between groups as noted in the figure legends. Plasma 
cholesterol was quantified as the area under the curve over the course of experiments. 




P<0.05. Bars in scatter dot plots represent mean ± SD. All images shown are 
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4.1. LDL accumulation precedes plaque development in mice 
Mouse models with inborn hypercholesterolemia, such as Apoe or Ldlr 
knockout mice, do not feature a clear starting point for the processes leading to plaque 
initiation. To study the temporal relationship between hypercholesterolemia onset, 
intimal LDL accumulation, and atherosclerosis initiation, we subjected 8-week-old 
wildtype mice to abrupt induction of hypercholesterolemia using virus-mediated 
transfer of proprotein convertase subtilisin/kexin type 9 (PCSK9) followed by a high-




Figure 12. Induction of atherosclerosis through PCSK9 overexpression. A, Experimental design. 
Groups of 8-week-old mice were injected with rAAV-PCSK9 and fed a high cholesterol (HC) diet for 0 
(n=7), 2 (n=7), 4 (n=7), 6 (n=7), or 12 weeks (n=7). B, Plasma LDL cholesterol concentration (mmol/L) 
at 8, 10, 12, 14, and 20 weeks of age. ****P<0.0001 (Kruskal-Wallis test). 
LDL accumulation was quantified in serial cross sections from the distal 
ascending aorta and the aortic root by staining for Apolipoprotein B (ApoB) (Figure 
13). The atherosclerosis-prone ascending aorta already showed significant ApoB 
accumulation across the inner part of the aortic arch after 2 weeks. This preceded the 
appearance of the first foam cells which were seen at 4 weeks in some mice, leading 
to a non-significant increase in measured intima area. Over the following weeks, the 
initially scattered foam cells progressed to lesions that eventually covered the entire 
inner aortic arch region. Concurrently, increasing ApoB staining was localized in 
developing plaques. The outer arch portion did not accumulate LDL or develop lesions 
over the time period studied. 
 




Figure 13. LDL accumulation and atherogenesis in mouse ascending aorta. A-B, LDL 
accumulation detected by staining for its protein moiety ApoB (brown) precedes plaque formation in the 
inner arch region of ascending aorta sections from mice subjected to 0, 2, 4, 6 and 12 weeks of 
hypercholesterolemia. Insets show selected areas at higher magnification. Scale bars, 200 µm in 
overview and 50 µm in insets. C-D, Quantification of ApoB accumulation and intima (plaque) area. 
ANOVA of log-transformed data (C) and Kruskal-Wallis test (D) followed by post-test comparison to 
normal aorta at 0w. ns, non-significant, **P<0.01, ****P<0.0001. 
Similar results were obtained in the aortic root. Each of the three sinuses 
showed significant ApoB accumulation at 2 weeks, and the level of accumulation at 
this stage correlated with the rate of subsequent lesion development, being highest in 
the most atherosclerosis-prone left coronary (LC) sinus and lowest in the less 
atherosclerosis-prone right coronary (RC) sinus (Figure 14).  
 




Figure 14. LDL accumulation and plaque development in mouse aortic root. A, Immunostaining 
for mouse ApoB (brown) in aortic sinus sections from mice injected with rAAV-PCSK9 and fed HC diet 
for 0w, 2w, 4w, 6w, or 12w. B, Higher magnification views of the area marked a box in A. C-E, 
Quantification of ApoB (LDL) accumulation in the left (LC), non- (NC), and right coronary (RC) aortic 
root sinus over time. F-H, Quantification of intima (plaque) area in each sinus over time. Scale bars, 
200 µm (A) and 50 µm (B). ANOVA of log-transformed data (C, D, E) and Kruskal-Wallis test (F, G, H) 
followed by post-test comparison to normal aortic sinus at 0w. ns, non-significant, *P<0.05, **P<0.01, 
****P<0.0001. 
Thus, as expected, LDL accumulation in PCSK9-induced mice precedes the 
initiation of lesions at atherosclerosis-prone sites in a pre-atherosclerotic phase. To 
understand the processes that regulate LDL accumulation, we then focused on the 
ascending aortic arch after 3.5 weeks of hypercholesterolemia. This time point is at 
the end of the pre-atherosclerotic phase at this site; close to the onset of 
atherosclerosis, but still with very few foam cells present. 
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4.2. Development and validation of high-resolution mapping 
methods for LDL entry and retention  
Buildup of LDL in the arterial wall is determined by the plasma LDL 
concentration and the capacity and regulation of LDL entry and retention mechanisms 
in the arterial wall. To study how LDL retention and entry mechanisms might control 
LDL accumulation in pre-atherosclerotic arteries, we set up several, including new, 
techniques to measure these processes using fluorescently labeled LDL following a 
previously published principle.128 Fluorescently–labeled human LDL particles were 
infused (tail vein injection) into mice followed by arterial flushing and perfusion-fixation 
after 1 hour or 18 hours. After 1 hour, when high concentrations of labeled LDL remain 
in the circulation, the amount of labeled LDL in arteries is a measure of the rate of LDL 
entry.128 After 18 hours, labeled LDL is mostly cleared from the plasma, and any LDL 




Figure 15. Method used to measure LDL entry and retention in arteries. Mice were injected with 
labeled LDL and the amount of labeled LDL in the arterial wall was analyzed after 1 hour or 18 hours 
to measure the rate of LDL entry and LDL retention, respectively. 
Figure 16 shows examples of the localization of injected Atto647-labeled LDL 
in aortic arch cross-sections from mice after 3.5 weeks hypercholesterolemia. After 1 
hour, labeled LDL localized around and inside arterial endothelial cells as expected 
for LDL entering the artery wall, while 18 hours after infusion, labeled LDL localized 
mainly in the sub-endothelial space as expected for LDL being retained within the 
artery wall. 
 




Figure 16. Localization of labeled LDL entered and retained in the artery wall. Aortic arch cross 
sections showing localization of Atto-647 LDL (grey) 1h (LDL entry) and 18h (LDL retention) after 
infusion in the artery wall of inner curvature region. DAPI (blue), autofluorescence (green). Similar 
images were obtained from n=4 mice/group. L=lumen, OC= Outer curvature, IC= Inner curvature. Scale 
bars, 20 µm. 
To produce high-resolution maps of the rates of fluorescent-LDL entry across 
the aortic arch, we labeled LDL with the near-infrared fluorophore Atto680 and imaged 
the quantity and location of labeled LDL after 1 and 18 hours by en face infrared (IR) 
scanning of the opened aorta. Representative pilot scans are shown of the distribution 
of LDL entry and retention rates across the pre-atherosclerotic surface after 3.5 weeks 
of PCSK9-induced hypercholesterolemia (Figure 17A). LDL entry and retention were 
mainly seen at branch points and in the inner curvature region of the aortic arch, but 
there was reproducible sparing of both entry and retention in the most central zone of 
the inner arch. The en face scanning technique was previously developed by our 
research group,72 but its merits as a quantitative measure of labeled LDL had not yet 
been validated. To confirm that scan intensity was proportional to the amount of 
labeled LDL in the artery, 3.5w hypercholesterolemic mice were injected with a mix of 
unlabeled/labeled LDL with increasing percentages of Atto680-labeled LDL (from 0% 
to 100%). After 18 hours, we measured the amount of retained LDL in the artery and 
observed a linear relationship between the Atto680 signal and the amount of injected 
labeled LDL (Figure 18).  
As an alternative technique that allows mapping of LDL entry and retention in 
the same specimen, we developed a whole-mount confocal protocol for imaging aortic 
arches from mice injected with Atto568-LDL and/or Atto647-LDL at the different time 
points (Figure 17B). For confocal scans, we found that an alternative approach to 
opening the aortic arch was preferable to preserve the atherosclerosis-prone inner 
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curvature region. The distribution of labeled LDL was consistent with the en face 
scanning results; high entry and retention were detected at the brachiocephalic branch 
point (not shown in figure) and in a border zone separating the inner curvature from 
the rest of the artery, whereas less signal was detected in the central zone of the inner 




Figure 17. LDL entry and retention measurement techniques. A, En face scanning of arterial 
Atto680-LDL content. Aortas were opened as indicated and scanned with an infrared scanner. 
Representative images show the rates of Atto680-LDL entry and retention (black dots) across the aortic 
arch in 3.5 weeks hypercholesterolemic mice. Scale bars, 1 mm. B, Whole-mount confocal microscopy 
of Atto565/647-LDL content. Aortas were opened as indicated. Representative images of the aortic 
inner curvature region show the distribution of Atto565-LDL entry (red) and Atto647-LDL retention (gray) 
across the aortic arch in 3.5 weeks hypercholesterolemic mice. Scale bars, 200 µm. 




Figure 18. Linear relationship between fluorescent signal and arterial wall content of Atto680-
LDL. A, Mice with different amounts of retained Atto680-LDL were created by injecting 500 mg of a mix 
of unlabeled-labeled LDL with increasing percentages of Atto680-LDL (n=4 per group). Scale bars, 1 
mm. The images show representative en face scans of aortas of 3.5 weeks hypercholesterolemic mice, 
harvested at 18h after the injection. Scale bars, 1 mm. B, Quantification of images showing a linear 
relationship between the amount of injected Atto680–LDL and the fluorescence signal. P****<0.0001 
(Ordinary one-way ANOVA). 
 
 
4.3. PCSK9 does not directly affect LDL entry or retention 
PCSK9 has been shown to bind both LDL and proteoglycans,129,130 raising the 
possibility that PCSK9 could act as a bridging molecule in LDL retention. Apart from 
its clear relevance to understanding PCSK9 function, such an interaction could bias 
measurements of LDL retention when using PCSK9 as a tool to manipulate plasma 
LDL levels. To test for this possibility, we injected rAAV-PCSK9 or rAAV-empty control 
vectors into groups of Ldlr knockout (Ldlr−/−) mice and compared entry and retention 
of Atto680-LDL after 3.5 weeks (Figure 19A). 





Figure 19. Atto680-LDL entry and retention in Ldlr knockout mice injected with rAAV-PCSK9 or 
rAAV-empty viral vectors. A, Experimental design. Ldlr−/− mice were injected with rAAV-PCSK9 
(PCSK9 group) or a similar rAAV-control without the PCSK9 sequence (control group) and fed standard 
chow diet for 3.5 weeks. They were then injected with Atto680-LDL at 1 hour (n=6 PCSK9 and n=7 
control mice) or 18 hours (n=8 PCSK9 and n=8 control mice) before termination to measure LDL entry 
and retention, respectively. B, Plasma LDL cholesterol concentration (mmol/L) in PCSK9 (n=6) and 
control (n=7) mice. ns, non-significant for comparison of the area-under-the-curve (AUC) (Mann-
Whitney test). C, Atto680-LDL entry at 1 hour post-infusion showing no significant difference between 
the two groups (n=6 PCSK9 and n=7 control mice). ns, non-significant (Mann-Whitney test). D, Atto680-
LDL retention at 18 hours post-infusion showing no significant difference between the two groups (n=8 
PCSK9 and n=8 control mice). ns, non-significant (Mann-Whitney test). 
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Consistent with PCSK9 causing hypercholesterolemia by lowering hepatic LDL 
receptor content, we found no effect on plasma LDL concentration in mice lacking the 
LDLR (Figure 19B). Quantification of aortic en face scans of Atto680-LDL also 
showed no significant effect of PCSK9 on LDL entry or retention (Figure 19C-D). The 
similar Atto680-LDL entry and retention observed between the two groups confirmed 
that PCSK9 overexpression can be used to study arterial LDL accumulation during 
hypercholesterolemia without undue interference. 
 
 
4.4. LDL retention is rate limiting for LDL accumulation in pre-
atherosclerotic arteries  
After developing tools to map arterial LDL uptake in the aortic arch of mice with 
PCSK9-induced hypercholesterolemia, we applied them to investigate whether rates 
of LDL entry or retention are changed in pre-atherosclerotic arteries compared with 
the normal arterial wall. The accumulation of LDL might itself influence the 
mechanisms of entry and retention creating positive or negative feedback loops that 
could shape the course of LDL accumulation and atherosclerosis onset. To address 
that question, comparison of PCSK9-overexpressing and wild-type mice was not an 
option, since the vast difference in hepatic LDL clearance would affect the plasma 
levels of labeled LDL and hence the quantification of LDL retention and entry. 
Therefore, we treated two groups of mice with rAAV-PCSK9 and the high-cholesterol 
diet, but in one of the groups we kept plasma LDL at normal levels by treating with 
antisense oligonucleotides targeting Apoliporotein B (ApoB ASO) (Figure 20A-B). The 
ApoB ASO promotes hepatic ApoB mRNA degradation, leading to a reduction in 
hepatic very-low-density lipoprotein (VLDL) output and hence lower plasma LDL 
levels. The other group was treated with a control antisense oligonucleotide (Ctrl 
ASO). After 3.5 weeks with high or normal plasma LDL, we conducted the LDL 
retention and entry assays after injection of the same Atto680-LDL dose in both 
groups. Clearance of the Atto680-LDL between the pre-atherosclerotic and normal 
mice was confirmed to be comparable at both 18 hours and 1 hour after injection 
(Figure 20C).  
The total rate of LDL entry and retention across the aortic arch was measured 
by the en face technique. Total entry of Atto680-LDL was significantly higher while 
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total retention was significantly lower in mice after 3.5 weeks of hypercholesterolemia 




Figure 20. Experimental design to compare LDL entry and retention in pre-atherosclerotic and 
normal arteries. A, By combining rAAV-PCSK9, high cholesterol (HC) diet and ApoB or Control anti-
sense oligonucleotides (ASOs), mice were assigned to high LDL cholesterol (pre-atherosclerotic 
arteries/Ctrl ASO) or normal LDL cholesterol (normal arteries/ApoB ASO) groups. Entry and retention 
of injected fluorescent-LDL were measured after 3.5 weeks. B, Plasma LDL cholesterol concentration 
(mmol/L) in pre-atherosclerotic (n=13) and normal aortas (n=15). ****P<0.0001 (Mann-Whitney test) 
comparing area-under-the-curve (AUC). C, Level of labeled-LDL was measured in plasma with a 
fluorometer and was found to be similar between groups both at 1h (n=8 mice/group) and 18h (n=9 
mice/group) after infusion indicating similar LDL clearance rates. Additional mice (n=5) mice were not 
infused with labeled LDL as a control. ns, non-significant (Mann-Whitney test). 
These findings show that the rate of LDL accumulation is not simply determined 
by plasma LDL levels but involves changes in both entry and retention mechanisms. 
The total entry of LDL in the pre-atherosclerotic phase was even higher than predicted 
by the increase in plasma LDL levels, whereas the amount of total retained LDL was 
lower than expected. These two observations combined suggest that the global 
capacity of the artery wall for LDL retention is saturated in hypercholesterolemic mice 
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and that retention is the overall rate-limiting step for LDL accumulation during the pre-




Figure 21. Global LDL retention is reduced despite increased entry into the pre-atherosclerotic 
aorta. A, Total Atto680-LDL entry in pre-atherosclerotic (n=7) and normal aortas (n=7) at 1 hour after 
infusion.  **P<0.01, Mann-Whitney test. B, Total Atto680-LDL retention in pre-atherosclerotic (n=8) and 
normal aortas (n=9) at 18 hours after infusion. ***P<0.001 (Mann-Whitney test). Scale bars, 1 mm. 
 
 
4.5. Rates of total LDL entry, but not retention, increase during the 
pre-atherosclerotic phase 
To corroborate these results with an alternative approach, we analyzed how 
total LDL entry and retention rates change during the first weeks after the onset of 
hypercholesterolemia. For this, we treated mice with rAAV-PCSK9 injection and 
initiated the high-cholesterol diet 4 weeks, 2 weeks, or 1 week before measuring 
Atto680-LDL entry and retention by the en face technique (Figure 22A-B). The 
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experimental design was chosen so that assays could be performed with the same 
batch of Atto680-LDL to allow direct comparison.  
 
 
Figure 22. Progression of total LDL entry and retention during the pre-atherosclerotic phase. A, 
Experimental design. Groups of mice were injected with rAAV-PCSK9 and fed a high cholesterol (HC) 
diet for 1, 2, or 4 weeks before measurement of LDL entry and retention at 12 weeks of age. B, Plasma 
LDL cholesterol concentration (mmol/L) in the three groups at 8, 9, 10, 11 and 12 weeks of age. 
***P<0.0001 (Kruskal-Wallis test) comparing area-under-the-curve (AUC). C, Atto680-LDL entry after 1 
hour in thoracic aortas exposed to hypercholesterolemia (HCL) for 1 (n=9), 2 (n=9), and 4 (n=7) weeks. 
Quantification of total signal shows an increasing rate of total LDL entry during the pre-atherosclerotic 
phase. **P<0.01 (Kruskal-Wallis test). D, Atto680-LDL retention after 18 hours in pre-atherosclerotic 
thoracic aortas exposed to hypercholesterolemia for 1 (n=7), 2 (n=7), and 4 (n=8) weeks. Quantification 
of total signal shows no changes in the rate of total LDL retention during the pre-atherosclerotic phase. 
ns, non-significant (Kruskal-Wallis test). 
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Significant increases in the total rate of Atto680-LDL entry were observed 
during the pre-atherosclerotic phase (Figure 22C), but this was not paralleled by 
increases in the total rate of retention (Figure 22D). This result confirms that the rate 
of LDL retention, but not that of LDL entry, is the limiting factor for total LDL 
accumulation in the mouse aortic arch during the pre-atherosclerotic phase.  
 
 
4.6. Gene expression changes in pre-atherosclerotic arteries 
The differences in LDL entry and retention rates of pre-atherosclerotic 
compared with normal arteries could potentially be caused by upregulation of genes 
facilitating endothelial transcytosis and downregulation of LDL retaining matrix 
molecules, respectively. To probe for such changes, we measured gene expression 
at the atherosclerosis-prone inner aortic curvature region in the presence of normal 
and high LDL levels through RNA-seq. We used the same experimental set up shown 
in Figure 20, but after 3.5 weeks we isolated the inner curvature region of pre-
atherosclerotic and normal arteries for total RNA isolation and high-throughput 




Figure 23. Analysis of gene expression changes in pre-atherosclerotic arteries. Mice were 
injected with rAAV-PCSK9 and fed high cholesterol (HC) and then treated with either ApoB ASO to 
reduce plasma LDL to normal levels (n=9) or a Ctrl ASO to maintain hypercholesterolemia (n=9) for 3.5 
weeks. RNA was isolated from the inner curvature region of the aortic arch, pooled (3 pools of n=3 
mice/group), and sequenced (RNA-seq). 
We identified 117 differentially expressed genes with an adjusted P-
value of <0.05. In the hypercholesterolemic setting, 23 genes were upregulated 
and 94 downregulated (Figure 24A).  




Figure 24. Regulated genes in pre-atherosclerotic arteries. A, RNA-seq data showing the 117 
differentially expressed genes (Adjusted P-value <0.05) in the atherosclerosis-prone inner curvature 
region after 3.5 weeks of hypercholesterolemia. B, Ingenuity Pathway Analysis (IPA) of the identified 
differentially expressed genes showing an over-representation of genes involved in lipid metabolism. 
Srebpf2 was found to be the most significant predicted upstream regulator. 
Among the upregulated genes we identified Abca1, a pivotal regulator of 
cholesterol efflux. Among the downregulated we identified Ldlr, known to be 
downregulated in cells by cholesterol overload. The Ingenuity Pathway Analysis (IPA) 
of our differentially expressed genes, showed, among the significant affected cellular 
functions, an over-representation of lipid metabolism with the most significant 
annotation being Cholesterol metabolism (Figure 24B). Among the most significant 
predicted upstream regulators that might explain the changes observed in our data, 
the ingenuity pathway analysis identifies Srebf2, whose inhibition would explain the 
upregulation of Abca1 and downregulation of Ldlr.131,132 These data are consistent with 
cholesterol overload of arterial cells that may reduce the intracellular capacity to 
degrade LDL, therefore facilitating the accumulation of LDL in the sub-endothelial 
space until saturation. However, this suggestion is only speculative and requires 
further investigation.  
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We did not identify differential expression of genes that have been described to 
be directly involved in LDL retention, such as the LDL-binding proteoglycans versican, 
perlecan, decorin, biglycan, syndecan-4, and LPL or LDL aggregating enzymes, such 
as sphingomyelinase or lipoprotein associated phospholipase A2. Neither did we 
identify changes in genes for caveolae proteins and endothelial receptors involved in 
arterial LDL transcytosis, such as Caveolin-1 (CAV-1) and Scavenger receptor class 
B type 1 (SR-B1) and the Activin receptor-like kinase (ALK-1). This could suggest that 
the increase in total LDL entry and saturable total LDL retention observed at the 
atherosclerosis-prone inner curvature region of pre-atherosclerotic arteries, may be 
caused by indirect mechanisms, such as saturation of the capacity of retention or 
increases in paracellular endothelial transport. However, this experiment has the 
limitation of analyzing global gene expression changes occurring in all the cells within 
the artery wall of the inner curvature region, which may prevent from identifying 
potential differentially expressed genes within the arterial endothelial compartment or 
inner media and at the exact sites of LDL accumulation. Endothelial RNA-seq or 
single-cell RNA-seq (scRNA-seq) of the arterial wall may yield further insights on the 
gene expression changes that characterize the pre-atherosclerotic phase. 
 
 
4.7. Changes in LDL entry and retention are heterogeneous across 
the aortic arch  
Further inspection of the en face scans used to measure LDL entry and 
retention in pre-atherosclerotic and normal arteries (Figure 21) suggested that the 
global measurements did not capture the changes occurring in local regions of the 
aortic arch. As already observed in the pilot scans (Figure 17), pre-atherosclerotic 
aortic arches did not show homogeneous high levels of LDL entry and retention in the 
inner curvature region, although this area is generally thought to be uniformly 
atherosclerosis-prone. The intensity was higher in longitudinal zones on the ventral 
and dorsal aortic arch wall (from here on border zones) that lie between the central 
zone of the inner arch (from here on central inner zone) and the outer curvature region 
(from here on outer zone). The sparing of the central inner zone in 
hypercholesterolemic mice was unexpected since ApoB immunostaining detected 
LDL accumulation in the entire inner arch at 2 to 4 weeks of hypercholesterolemia 
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(Figure 13A). Moreover, the pattern appeared different from that of normal aortas, in 
which retention was more uniform across the central part of the inner curvature region. 
These observations raised the possibility that not only the level but also the topography 
of retention may change as arteries accumulate LDL.  
To quantify this, we divided the dorsal leaf of the opened aortic arch into central 
inner, border, and outer zone, defined as indicated in Figure 25A. We then analyzed 
the intensity profiles of the LDL entry and retention signals in these zones in the en 




Figure 25. Topography of LDL entry and retention distribution across the aortic arch in en face 
scans. A, Schematic representation of the division of the ascending aortic arch in zones: central inner 
zone (CZ), border zone (BZ), and outer zone (OZ). B, En face analysis (inverted grey-scale) of Atto680-
LDL entry in pre-atherosclerotic (n=8) and normal (n=7) arteries, along the zones of the dorsal aortic 
arch. Intensities were measured along a perpendicular line proximal to the branch point of the 
brachiocephalic artery. Mean intensity was increased overall (total area-under-the-curve, AUC), and 
this was explained by increased intensity in the border zone. Graphs show mean±SD. ns, non-
significant, *P<0.05 for AUC (Mann-Whitney test). Scale bars, 1 mm. C, En face analysis of Atto680-
LDL retention, showing overall significantly lower LDL retention in pre-atherosclerotic aortas (n=6) than 
in normal aortas (n=9), explained by reduced retention in the central inner zone. Graphs show 
mean±SD. ns, non-significant, *P<0.05, **P<0.01 for AUC (Mann-Whitney test). Scale bars, 1 mm. 
Compared with normal aortas, pre-atherosclerotic aortas showed significantly 
higher Atto680-LDL entry in the border zone of the inner arch (Figure 25B). 
Conversely, retention was unchanged in the border zone of pre-atherosclerotic 
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compared with normal aortas and was even significantly lower in the central inner zone 
(Figure 25C). This shows that even though LDL accumulates throughout the inner 
curvature, the dynamics of LDL entry and retention differ greatly across the aortic arch. 
In the central inner zone (CZ) of the pre-atherosclerotic aortic arch, there is moderate 
LDL entry and saturated LDL retention; in contrast, in the border zone (BZ), LDL entry 
is high and retention mechanisms are not saturated. 
To corroborate these observations, we analyzed the topographical pattern of 
entry and retention by whole-mount confocal microscopy in new groups of mice after 
3.5 weeks of hyper- or normocholesterolemia (following again the experimental design 
shown in Figure 20). In this case, the analysis focused only on the border and central 




Figure 26. Topography of LDL entry and retention distribution across the aortic arch in whole-
mount images. A, Schematic representation of the inner part of the aortic arch divided into zones: 
dorsal border zone (BZ), central inner zone (CZ) and ventral border zone (BZ). B, Whole-mount 
confocal microscopy distribution of labeled LDL (red) in the inner aortic arch region of pre-
atherosclerotic (left) and normal mice (right). Intensity profiles across the thick line indicate higher entry 
in the border zones of pre-atherosclerotic aortas (n=9) than in the equivalent regions of normal aortas 
(n=6). Graphs show mean±SD. ns, non-significant, *P<0.05 for AUC (Mann-Whitney test). Scale bars, 
500 µm. C, Whole-mount confocal microscopy analysis of retained labeled LDL (gray) showing lower 
retention in the central inner zone of pre-atherosclerotic aorta (n=9) than in the equivalent region of 
normal aortas (n=6), where the retention is uniform across the central inner and border zones. Graphs 
show mean±SD. ns, non-significant, **P<0.01 for AUC (Mann-Whitney test). Scale bars, 500µm. 
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To enable analysis of entry and retention in the same aortas, mice were injected 
with two types of labeled LDL: half the mice received Atto647-LDL at 18 hours before 
and Atto565-LDL at 1 hour before sacrifice and the rest vice versa. This design was 
chosen to control for potential differences in fluorescence intensity in the co-
localization analysis. Visual inspection and measured intensity profiles confirmed that 
entry and retention rates were higher in the border zones than in the central inner zone 
of pre-atherosclerotic aortas, whereas in normal aortas, retention was more uniform 
across the inner curvature region (central and border zones) (Figure 26B-C). 
Consequently, pre-atherosclerotic aortas showed significantly higher co-
localization between LDL entry and retention than normal aortas (Figure 27A). To 
explore what characterizes these sites of high entry and retention in pre-
atherosclerotic aortas, we post-stained aortas for macrophages. Macrophages were 
predominantly found in the border zones of the inner curvature region, and areas with 




Figure 27. The border zones of the inner curvature region in pre-atherosclerotic aortas show 
high rates of LDL entry and retention. A. Whole-mount confocal microscopy analysis of the co-
localization of labeled LDL entry (red) and retention (gray) in the inner curvature region of pre-
atherosclerotic (left) and normal mice (right). The graphic represents aortic areas with LDL entry and 
retention, showing significantly higher overlap between entry and retention in pre-atherosclerotic aortas 
(n=9) than in normal aortas (n=6). *P<0.05 (Mann-Whitney test). Scale bars, 500 µm. B, Post-staining 
for macrophages (Mac2+) showed that the scattered macrophages at this stage clustered visually in 
the border zones and that macrophage-rich regions had higher rates of LDL retention compared with 
macrophage-low areas. Bars show mean±SD. **P<0.01 (Mann-Whitney test). Scale bars, 500 µm.  
The combined data thus suggest that during the pre-atherosclerotic phase, the 
high level of incoming LDL saturates retention in the central inner zone of the aortic 
arch, whereas entry and retention continue unimpeded in the border zones where the 
first macrophages also accumulate. 
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4.8. Saturation of LDL retention is intrinsic to the arterial wall  
The reduction in the retention of fluorescent LDL in the central inner zone of 
pre-atherosclerotic aortas indicated saturation of LDL retention mechanisms, which 
could occur by several mechanisms. First, it could be caused by simple competition 
from the high levels of LDL in the plasma of pre-atherosclerotic mice, similar to classic 
experiments where saturable binding of a labeled protein is revealed by outcompeting 
it with unlabeled protein. Second, it could be due to intrinsic properties of the pre-
atherosclerotic artery wall, such as exhaustion of remaining binding sites for LDL in 
the extracellular matrix after weeks of LDL entry, changes in the extracellular matrix, 
or other cellular regulation of retention mechanisms.  
To distinguish between these two possibilities, we first assessed retention 
shortly after the induction of hypercholesterolemia. If saturation was caused by simple 
competition of unlabeled LDL, induction of hypercholesterolemia itself should reduce 
retention of injected labeled LDL. Groups of mice were administered rAAV-PCSK9, 
started on the high-cholesterol diet, and given a single injection of ApoB or Ctrl ASO. 
After 3 days with high or normal LDL levels, both groups received injections of the 
same dose of Atto647-LDL, and retention was analyzed by whole-mount confocal 




Figure 28. Effect of short-term hypercholesterolemia on LDL retention. A, Experimental design. 
Groups of mice were injected with rAAV-PCSK9, fed a high-cholesterol (HC) diet, and given a single 
injection of either Ctrl ASO (3d LDL­, n=5) or ApoB ASO (Normal, n=5). LDL retention assays were 
performed after 3 days. B, Plasma LDL cholesterol concentration (mmol/L). ***P<0.001 (Mann-Whitney 
test at 3d). 
The experiment was done under the assumption that short-term 
hypercholesterolemia (3 days) does not induce important changes in the capacity of 
LDL retention in the artery wall, therefore allowing to test solely the competition 
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between injected labeled LDL and high levels of endogenous unlabeled LDL for the 
intimal LDL binding sites in the arterial wall. 
We found that the LDL retention pattern was uniform throughout the inner 
curvature region (central inner and border zones) in both groups, indicating that an 
increase in circulating LDL alone is not sufficient to cause saturation of LDL retention 




Figure 29. LDL retention after 3 days of hypercholesterolemia. Whole-mount confocal microscopy 
analysis of the inner curvature region of the aortic arch. Intensity profiles across the indicated thick line 
show uniform retention of Atto647-LDL across the central inner (CZ) and border zones (BZs) in 3-day 
hypercholesterolemic and normal aortas. Graphs show mean±SD. ns, non-significant for AUC (Mann-
Whitney test). Scale bars 500µm. 
In a second approach, we tested whether established saturation was quickly 
reversed after rapid LDL lowering. If saturation was caused by simple competition of 
labeled LDL retention from unlabeled LDL in plasma, reversal of hypercholesterolemia 
itself should increase retention of labeled LDL. To investigate this, we repeated our 
standard experiment with hypercholesterolemic and normocholesterolemic mice, but 
lowered LDL cholesterol in the hypercholesterolemic group with a single high dose of 
ApoB ASO (10 mg/kg) 3 days before analyzing Atto680-labeled LDL retention at 3.5 
weeks (Figure 30A). The final plasma LDL concentration was similar in the two groups 
(Figure 30B). This allowed us to test the rate of retention of labeled LDL in pre-
atherosclerotic and normal arteries in the absence of competition from high levels of 
endogenous unlabeled LDL. Notably, the experiment was done under the assumption 
that 3 weeks of sustained hypercholesterolemia (compared with 3.5 weeks in previous 
experiments) was already sufficient to induce the pre-atherosclerotic changes in the 
artery and that 3 days of LDL lowering was not sufficient to reverse them.  




Figure 30. Effect of rapid hypercholesterolemia reversal on LDL retention. A, Experimental design. 
Two groups of mice were injected with rAAV-PCSK9 and started on the HC diet. One group received 
weekly ApoB ASO injections to maintain normal plasma LDL (n=9, Normal) and was analyzed for LDL 
retention at 3.5 weeks. The second group received weekly Ctrl ASO injections but was given a single 
high dose (10 mg/kg) injection of ApoB ASO 3 days before the endpoint to bring plasma LDL levels 
back down to normal (n=5, 3d LDL¯). B, Plasma LDL cholesterol concentration (mmol/L) curves 
showing comparable LDL levels between the two groups at endpoint. ns, non-significant (Mann-Whitney 
test at 3.5w). Bars show mean±SD. 
The intensity profile analysis showed that although competition from 
endogenous LDLs was removed, labeled LDL retention saturation was maintained in 




Figure 31. LDL retention after 3 days of LDL lowering. En face analysis (inverted grayscale) of 
Atto680-LDL retention. Intensity profiles along the indicated direction show persistent saturation of LDL 
retention in the central inner zone of 3d LDL¯ mice, whereas retention in the border zone was increased. 
Graphs show mean±SD. ns, non-significant, *P<0.05, **P<0.01 for AUC (Mann-Whitney test). Scale 
bars, 1 mm. 
This indicates that the reduced retention of labeled LDL in hypercholesterolemic 
mice involved changes intrinsic to the arterial wall and was not explained by simple 
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competition from circulating unlabeled LDL. In the border zone, retention of labeled 
LDL in the pre-atherosclerotic arterial wall was increased when competition from 
endogenous LDLs was removed. This may suggest that the capacity for retention in 
the border zone is increased compared with the normal artery, but that this is masked 
when analyzed in hypercholesterolemic mice because of competition from 
endogenous unlabeled LDL. 
Combined, the results obtained from the two experimental approaches suggest 
that the reduced retention of labeled LDL observed in the central zone of the inner 
curvature region is not caused by the difference in plasma LDL levels between 
hypercholesterolemic and normocholesterolemic mice, but by saturation of binding 




4.9. LDL entry and retention rates predict the course of plaque 
development  
To test whether the rates of LDL entry and retention in the pre-atherosclerotic 
wall predict the subsequent development of atherosclerosis, we injected mice with 
rAAV-PCSK9 and fed them the high-cholesterol diet for 0, 4, 6, 12, or 24 weeks 
(Figure 32). We then evaluated how the topography of the atherosclerotic lesions 
related to the topography of LDL entry and retention distribution across the aortic arch.  
 
 
Figure 32. Correlation between the topography of LDL entry and retention and topography of 
atherosclerotic lesions. A, Experimental design. Groups of 8-week-old mice were injected with rAAV-
PCSK9 and fed a high cholesterol (HC) diet for 0 (n=4), 4 (n=6), 6 (n=7), 12 (n=7), or 24 weeks (n=6). 
B, Plasma LDL cholesterol concentration (mmol/L) at 8, 12, 14, 20, and 32 weeks of age. ****P<0.0001 
(Kruskal-Wallis test). 
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Plaque formation was first evident at 6 weeks at the border zones of the inner 
curvature region. At 12 weeks of atherogenesis, plaques started to incorporate the 
central zone of the inner curvature region until completely covering it at 24 weeks. The 




Figure 33. LDL entry and retention rates in the pre-atherosclerotic wall predict how 
atherosclerosis develops. Representative images of the inner aortic arch examined with a Nikon 
stereomicroscope. Images show plaque formation starting at the border zones of the inner curvature 
region after 6w of hypercholesterolemia (n=7), developing toward the central zone after 12w (n=7) until 
becoming uniform across the inner arch after 24w (n=6). Border and central inner zones with 
atherosclerotic lesions are indicated with black arrows. Scale bars, 1 mm. 
 
 
4.10. Atherogenesis is associated with loss of saturation of LDL 
retention mechanisms 
To evaluate whether the saturation of LDL retention observed in the central 
inner zone of the pre-atherosclerotic aorta persists in lesioned arteries, we induced 
atherosclerosis in two groups of mice through rAAV-PCSK9 injection and high-
cholesterol diet for 12 weeks. In one group, one week prior to the endpoint, we rapidly 
reduced plasma LDL by single injection of high dose ApoB ASO (10 mg/kg); the other 
group received a single high dose of Ctrl ASO (Figure 34A-B).  
The experiment was done under the assumption that one week of 
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normocholesterolemia is not sufficient to induce changes in the biology of 
atherosclerosis (i.e. content of macrophages, foam cells, ECM composition, and gene 
expression changes of key cytokines and scavenger receptors), therefore allowing to 
test only the effect of different endogenous plasma LDL levels on the labeled LDL 




Figure 34. Atherogenesis is associated with loss of saturation of LDL retention mechanisms. A, 
Experimental design. 8 weeks old wild-type mice were injected with rAAV-PCSK9 and fed a high 
cholesterol (HC) diet for 12 weeks. One week before the endpoint, one group of mice received a high 
dose injection of ApoB ASO (10 mg/kg) (1w LDL¯, n=9) to lower LDL cholesterol. Another group 
received a single high dose of Ctrl ASO (Athero, n=9). B, Plasma LDL cholesterol concentration in the 
two groups after 0, 6, and 12 weeks. ns, non-significant, ****P<0.0001 (Mann-Whitney test at each time 
point). C, Representative aortic arch cross sections from Athero (n=9) and 1w LDL¯ (n=9) mice, 
showing Atto647-LDL retention (gray), macrophage content (red), and elastin autofluorescence (green). 
Scale bars, 20 µm. D-F, Quantification of plaque and macrophage area, showing no significant 
difference between the two groups (Mann-Whitney test). D, Quantification of Atto647-LDL retention 
area, showing that retention is not saturated by the high plasma LDL concentration in the Athero group. 
ns, non-significant (Mann-Whitney test). 
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At 18 hours after injection of Atto647-LDL, we analyzed aortic arch cross 
sections by confocal microscopy. As expected, plaque size and macrophage content 
were not changed by the short period of normal LDL levels. Notably, retention of 
Atto647-LDL was also similar in both groups, suggesting that once the atherosclerosis 
process starts, the saturation of LDL retention mechanisms observed during the pre-
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Atherosclerosis is a slowly progressing disease that starts in young adults but 
remains harmless for decades. It is an extremely widespread pathology and even 
individuals that never suffer symptoms from atherosclerotic disease and die from other 
causes often have considerable atherosclerotic lesion formation. In those individuals, 
atherogenesis was just not fast enough to lead to symptoms before death by other 
causes. Indeed, the goal for prevention is not so much to avoid atherosclerosis but to 
postpone the age of clinical symptom debut. In this context, understanding the initial 
stages of the disease has high importance as this could help provide tools to retard 
the time by which lesions are initiated and spread across the arterial tree and thereby 
result in a delay in life-threatening atherothrombotic complications.  
The focal pattern of lesion development is a striking feature of atherogenesis 
and studying the topography of atherosclerosis is an important inroad to understanding 
what leads to the onset of the disease and how it can be delayed. Lesions develop 
initially near branch sites and on the inside of arterial curvatures, while other regions 
take much longer to be affected and some are completely protected. There is little 
doubt that it is the selective accumulation of LDL at the most atherosclerosis-prone 
sites that causes the first lesion formation, but why LDL accumulates there and not 
elsewhere remains uncertain.11  
 
 
5.1. Functional studies reveal the importance of both LDL entry and 
LDL retention processes 
Both LDL entry and LDL retention are needed for LDL accumulation and as 
would be expected, functional studies show that blocking steps in either process can 
lead to a reduction in LDL accumulation and retardation of lesion formation. An 
overview of some of the interventions that have been studied and their effects is given 
in Figure 35.  
LDL entry can be inhibited by knockout of Caveolin 1, which is an important 
constituent of caveolae that carry LDL transcytosis through intimal endothelial cells. 
Lack of Cav1 causes reduced LDL entry and less atherosclerosis formation in 
mice.36,38 Also, knockout of the gene encoding SR-B1 in Apoe−/− or Ldlr−/− mice 
reduces LDL transcytosis and results in reduced atherosclerotic lesions compared to 
controls despite no change in circulating LDL levels.32 Notably, an earlier study 
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showed that the endothelium-specific over-expression of human SR-B1 also 
decreases atherosclerosis in Apoe−/− mice, suggesting that SR-B1 may play other 




Figure 35. Schematic representation of the functional studies showing LDL entry and LDL 
retention as necessary steps for atherosclerosis initiation. Details are discussed in the main text. 
EC= Endothelial cell; PG= Proteoglycans. 
Specific attenuation of the ability of LDLs to be retained in arteries has also 
been achieved in experimental models and has been found to delay atherosclerosis 
initiation. Skålén et al. showed that mutagenesis of the primary proteoglycan-binding 
site in ApoB results in reduced atherosclerosis in mice, independently of the effects 
on plasma LDL levels.134 Several other changes in the lipid and protein composition 
of LDL that result in increased affinity for proteoglycans have been shown to promote 
atherogenesis.47,51,135 In addition, changes in the arterial composition of LDL-binding 
proteoglycans affect the susceptibility to atherosclerosis. For example, Ldlr−/− mice 
overexpressing biglycan showed increased atherosclerosis development that 
correlated with vascular biglycan content.136 Biglycan deficiency did not exert the 
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expected protective role against the development of atherosclerosis in the same 
model. Yet, these mice showed increased vascular perlecan content, suggesting a 
response of the vasculature to compensate for the biglycan deficiency.137 Another 
example is given by Apoe −/− mice lacking the proteoglycan neural/glia antigen 2 
(NG2), able to bind LDL through hydrophobic interactions. Double knockout mice 
(Ng2−/−/Apoe−/−) show reduced LDL retention and develop less atherosclerosis 
compared to their Apoe −/− controls.138 Other manipulations of the arterial matrix that 
alter the content of LDL-binding proteoglycans also affect atherosclerosis 
initiation.139,140 For instance, the metalloprotease A disintegrin and metalloproteinase 
with thrombospondin motifs 5 (ADAMTS-5) is a major proteoglycan-degrading 
enzyme. Didangelos et al. showed that reduced activity of ADAMTS-5 results in 
proteoglycan accumulation, increased LDL retention in the artery wall, and increased 
atherosclerosis.139 Moreover, the handling of arterial-wall enzymes that promote LDL 
retention also influences atherosclerosis.128,141,142  
Finally, an informative study from Tran-Lundmark et al. allowed the separation 
of LDL entry and LDL retention by creating a genetic model with opposite effects on 
the two processes. They generated heparan sulfate (HS)-deficient perlecan 
(Hspg2∆3/∆3) mice with an Apoe−/− background. Perlecan is involved in LDL retention 
but also contributes to the endothelial barrier of the arterial wall. Hspg2∆3/∆3\Apoe−/− 
mice therefore exhibit increased LDL entry but lower LDL retention in the artery wall. 
They developed significantly reduced atherosclerotic lesions compared to Apoe−/− 
controls, suggesting a key role for LDL retention in atherogenesis, regardless of the 
LDL entry levels.11,143 Furthermore, experimental manipulation of blood flow that 
increases atherosclerosis susceptibility in mouse carotids increased LDL retention but 
not LDL entry.72  
These functional studies highlight the fact that both LDL entry and LDL retention 
are necessary steps for LDL accumulation and atherogenesis, but they do not speak 
to which is the rate-limiting mechanism during the natural history of atherosclerosis. 
 
 
5.2. Which process determines atherosclerosis susceptibility? 
Various studies have implicated either increased LDL entry or increased intimal 
LDL retention as the distinguishing feature of susceptible arterial regions. Early studies 
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in rabbits concluded that the entry of radiolabeled LDL into aortic segments predicted 
atherosclerosis development,26 but others found differing LDL accumulation in regions 
with similar LDL entry rates, indicating that selective LDL retention was the rate-limiting 
step.39 Therefore, results in this field have not been consistent, and it is clear that 
further investigation is needed of the association between topographical differences in 
LDL entry and retention and atherosclerosis susceptibility.  
The present study delivers a systematic analysis of LDL dynamics in the mouse 
aortic arch during early atherogenesis. We report entry and retention rates across 
susceptible and resistant regions and contrast them between normal arteries and 
arteries on their way to initiating atherosclerosis. This approach goes beyond previous 
analyses by providing higher resolution than achievable with radiolabeling and by 
using tools that allowed us to compare mice with high and normal plasma LDL without 
creating differences in the clearance of the labeled LDL probe. Using these tools, we 
obtained insights into how LDL entry and retention in the arterial wall predict the onset 
and progression of atherosclerotic lesions in the mouse. Our main findings are 
discussed in detail in the next sections. 
 
 
5.3. Rates of LDL entry and retention define regions with differing 
atherosclerosis susceptibility  
The first main finding of the thesis was that differences in LDL entry and 
retention rates in the normal (non-atherosclerotic) mouse aortic arch divide it into three 
regions with differing atherosclerosis susceptibility. The atherosclerosis-resistant zone 
(the outer part of the arch) takes up and retains little LDL and develops no 
atherosclerosis over 24 weeks of high plasma LDL. The intermediate-susceptibility 
zone in the central part of the inner arch retains LDL but does not have a high average 
rate of LDL entry; this zone is initially unaffected by atherosclerosis but develops it 
over 6-24 weeks. Finally, the highly susceptible border zones that lie between the 
resistant and intermediate-susceptibility regions on the lower ventral and dorsal walls 
of the aortic arch; these zones have high rates of both LDL entry and retention and 
are the location where lesions are initiated.  
These observations offer a unifying explanation for previous studies that have 
variably associated subsequent atherosclerosis development with the pattern of either 
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LDL entry or retention. We find that both LDL entry and retention are associated with 
atherosclerosis susceptibility but with different time horizons. The distribution of LDL 
entry in the normal artery predicts sites of imminent atherogenesis, whereas the 
distribution of retention predicts the surface area that will eventually be covered with 
lesions.  
Why these regions show different properties requires further investigation. 
Possibly, an important role could be played by the wall shear stress generated by the 
blood flow in the different regions. The outer zone of the aortic arch (atherosclerosis-
resistant region) is subjected to high laminar shear stress, which is athero-
protective.144–146 Areas of high laminar shear stress, in which endothelial cells are 
elongated, aligned, and protected from inflammation,74 have already been correlated 
with low rates of LDL entry and retention.26,39,70,117 Therefore, this part of our results 
confirms previous studies. Conversely, the inner aortic curvature region composed of 
both the central inner zone (intermediate-susceptibility region) and the border zones 
(highly-susceptibility region), is well known to be subjected to low wall shear stress.144–
146 Although this area has traditionally been referred to as homogeneously 
atherosclerosis-prone, this study shows the existence of site-specific dissimilarities. 
Therefore, there could be unknown additional regional differences within the inner 
curvature area, with the wall shear stress being lower and more disturbed at the border 
zones compared to the central inner zone.  
As discussed in the next sections, disturbed flow induces several changes in 
the arterial intima that could affect LDL entry, LDL retention, and inflammatory 
activation which in turn could play a key role in altering atherosclerosis-susceptibility.  
First, low shear stress increases endothelial permeability, which together with 
increased residence time of circulating LDL characteristic of flow stagnation areas, 
could increase rates of LDL entry.69,147 Local hemodynamics could also affect LDL 
entry by altering the thickness of the endothelial glycocalyx, a thick layer of 
glycoproteins and heparan sulfate (HS), hyaluronic acid (HA), and chondroitin sulfate 
(CS) proteoglycans that lines the endothelial surface and extends from the 
endothelium towards the lumen.148 The glycocalyx is an important barrier to solutes 
and is involved in the regulation of LDL transport into the arterial wall, although the 
exact nature of the interactions between LDL and glycocalyx is not well understood.149 
The extent of the glycocalyx depends on both synthesis and endothelial apoptosis 
rates.149 High shear stress has been shown to reduce the rate of endothelial cell 
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apoptosis150,151 and to increase endothelial cell synthesis of glycocalyx 
components.152,153 This is consistent with the observation that the glycocalyx is highest 
at atherosclerosis-resistant sites and thinnest at atherosclerosis-prone sites. Upon 
cholesterol challenge, it is reduced in all the arterial zones.154,155  
Second, lowered wall shear stress or accompanying differences in tensile 
stress of the arterial wall could influence local vascular smooth muscle cells (VSMCs) 
to modulate and secrete LDL-binding matrix components, including proteoglycans.23 
Notably, the introduction of disturbed laminar flow in atherosclerosis-resistant arterial 
segments was shown to be sufficient to increase LDL retention.72 In the present study, 
LDL retention appeared uniform across the whole inner curvature region (border zones 
and central inner zone) in the normal mouse aortic arch. However, it is still possible 
that differential blood flow profiles within the inner curvature region may favor LDL-
binding intimal matrix synthesis in the border zones compared to the central inner 
zone. This increased capacity may only become visible once the available binding 
sites begin to be saturated by sustained hypercholesterolemia and not under 
normocholesterolemic conditions because of the overabundance of free binding sites.  
Third, altered wall shear stress may prime the endothelium to respond to pro-
atherogenic stimuli by enhancing inflammation.14,146,156 High laminar shear stress 
suppresses pro-inflammatory activation and leukocyte recruitment,157,158 while low 
sheer stress promotes a pro-inflammatory state with activation of pro-inflammatory 
signaling pathways (i.e. NF-kB signaling pathway).146 This pathway, in turn, activates 
genes implicated in atherosclerosis, such as genes encoding adhesion molecules (i.e. 
VCAM-1 and ICAM-1)159 and chemoattractants (i.e. MCP-1)160 that stimulate the 
recruitment of inflammatory cells into the sub-endothelial space. Studies of these 
pathways have generally considered the inner curvature region as a whole and future 
studies are needed to explore whether pro-inflammatory signaling is particularly 
abundant in the border zones. Consistent with that idea, we found that initial 
macrophages accumulated mostly at the border zones, which could potentially 
increase the capacity for LDL retention at these sites due to increased cellular uptake 
and release of pro-inflammatory cytokines stimulating extracellular matrix synthesis. 
We cannot, however, determine in the present study whether macrophages were 
recruited to the border zones because of the special LDL handling processes at these 
sites or vice versa.   
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To explore whether flow-controlled mechanisms could explain the increased 
atherosclerosis susceptibility of the border zones, it would first be important to evaluate 
whether regional differences in wall shear stress exist between the border zones and 
the central inner zone of the inner curvature region. To do so, an important step would 
be to perform careful measurements of the geometries followed by blood flow 
modeling by computational fluid dynamics, directing special attention to the 
heterogeneity of the inner curvature area. Moreover, it would be interesting to map 
glycocalyx thickness, components of endothelial junctions, proteoglycan composition 
and differential expression of LDL transport elements (i.e. caveolae, CAV-1, SR-B1, 
ALK-1). This will require additional immunostaining, bulk or scRNA-seq gene 
expression profiling in micro-dissected tissues, and transmission electron microscopy 
(TEM). If promising associations are seen, intervention studies, e.g. enzymatic 
glycocalyx reduction or gene knockouts, could be performed to analyze the causal 
importance for the differences in atherosclerosis susceptibility across the aortic arch.  
 
 
5.4. The atherosclerosis-intermediate susceptibility region has 
saturable LDL retention  
The second main finding emerging from our analysis is that the intermediate 
susceptibility of the central zone of the inner curvature region is associated with 
saturation of LDL retention. This was evident from two experimental outcomes. First, 
global LDL entry rates in the aortic arch increased during the pre-atherosclerotic 
phase, but this was not mirrored by similar increases in the global rate of LDL retention. 
Second, pre-atherosclerotic arteries in hypercholesterolemic mice retained less total 
labeled LDL than arteries in normocholesterolemic mice, and this was explained by 
reduced retention in the central zone of inner curvature.  
The saturation of LDL retention mechanisms in the central inner zone was not 
due to competition from the high plasma concentration of endogenous LDL in the 
hypercholesterolemic mice, since it did not develop immediately after induction of 
hypercholesterolemia and did not disappear after a short period of 
normocholesterolemia. The first experiment was done under the assumption that 3 
days of hypercholesterolemia do not induce important changes in the artery wall, 
therefore allowing to test only the competition from high levels of endogenous LDL for 
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intimal LDL binding sites. To our knowledge, the impact of such short-term 
hypercholesterolemia on arterial wall composition has not been directly tested, but we 
find it reasonable that major changes are not induced. The second experiment was 
done under the assumption that 3 weeks of sustained hypercholesterolemia are 
sufficient to induce the pre-atherosclerotic changes in the artery and that 3 days of 
LDL lowering is not sufficient to reverse them. Although quantitative analysis has not 
been done, visual inspection of the en face scans from mice during the first weeks of 
hypercholesterolemia suggests higher LDL entry at the border zones and lower LDL 
retention in the central inner zone already at 2 weeks, supporting this hypothesis. 
Llodrà et al., showed increased arterial clearance of monocytes to lymphoid organs 
from aortic lesions exposed to 3 days of normocholesterolemia by aortic 
transplantation from atherosclerotic Ldlr −/− mice into wild-type mice.161 Using this 
model, the authors also observed plaque size reduction after 3 days, which, however, 
was not observed by Bartels et al. after 1 week of LDL lowering with ApoB ASO 
treatment in atherosclerotic Ldlr −/− mice.117 To our knowledge, short-term 
hypercholesterolemia reversal has not been tested in pre-atherosclerotic mice, 
therefore we should keep awareness of the limitations of the assumption.  
Notably, in the central zone of the inner curvature region there was no 
saturation at the level of LDL entry, which was similar between pre-atherosclerotic and 
normal mice. The combined observations therefore suggest that, during the pre-
atherosclerotic phase, the intima has a limited capacity for binding LDL and that when 
this capacity is reached most incoming LDL returns to the circulation from the vessel 
wall without being retained.  
It is important to keep in mind that, although hypercholesterolemic mice play a 
central role in the investigation of the pathogenesis of atherosclerosis, they do not 
recapitulate all the features of the human disease. Indeed, while early lesions in 
humans are characterized by adaptive intimal thickening, this is not the case in 
mice.108 Therefore, the saturable LDL binding capacity of the artery wall observed in 
pre-atherosclerotic mouse arteries might not occur in humans, where adaptive intimal 
thickenings can grow to be as thick as the underlying media.73 Also, heterologous 
(human) LDL could have different binding affinities to arterial wall receptors and intimal 
matrix from homologous (mouse) LDL.21,162  
In order to understand why the saturation of LDL retention occurs, it would be 
of interest to evaluate whether it is linked to the limited capacity of the LDL binding 
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sites. A logical step would be to evaluate whether LDL retention saturation in the 
central inner zone is maintained after induction of intimal hyperplasia163 and thereby 
in the presence of increased intimal tissue volume and total number of LDL binding 
sites. In vitro LDL-binding assays163 on frozen aortic arch cross sections from pre-
atherosclerotic and normal mice could also give insights on the LDL binding capacity 
of the artery wall. Global gene expression analysis at the inner aortic curvature region 
in pre-atherosclerotic and normal arteries did not show differential expression of 
extracellular matrix proteoglycans. However, the analysis was done taking into 
account the whole artery wall of the inner curvature region, not allowing to differentiate 
between the border and central inner zones. RNA-sequencing and differential gene 
expression analysis after micro-dissection of the border and central zones of the inner 
curvature region could provide a better understanding of this phenomenon.  
 
 
5.5. The conversion from saturable to non-saturable LDL retention 
accompanies the onset of atherosclerosis 
The third main finding is that conversion from saturable to non-saturable LDL 
retention accompanies the onset of atherosclerosis. We found comparable retention 
of labeled LDL at sites of atherogenesis whether plasma LDL was high or was lowered 
shortly before analysis, including in the central zone of the inner curvature region. This 
indicates that the capacity for retention of incoming LDL increases substantially with 
initiation of atherosclerosis and that it shows no saturation even in the presence of 
high plasma LDL levels in hypercholesterolemic mice.  
The experiment was done under the assumption that one week of 
normocholesterolemia is not sufficient to induce changes in the atherosclerotic artery 
wall. The absence of saturation for LDL retention in mature plaques is consistent with 
previous findings by Bartels et al., who measured an unchanged pool size of 
radiolabeled LDL within the arterial wall after 1 week of LDL lowering in atherosclerotic 
Ldlr −/− mice kept on a high-cholesterol diet for 16 to 19 weeks.117 However, in the 
latter study they also observed an improved barrier function of the aortic endothelium 
towards the entry of plasma radiolabeled LDL particles after 1 week of treatment with 
ApoB ASO.117 Potentially, a lower LDL entry could influence our retention assay in 
mature plaques if LDL entry was a limiting factor for LDL intimal binding. This was not 
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the case in pre-atherosclerotic animals, but the possibility cannot be excluded and 
further investigation is required to test this. Moreover, as mentioned in the previous 
section, Llodrà et al. showed increased migration of monocytes from the artery wall to 
lymph nodes shortly after the induction of lowered LDL plasma levels through aortic 
transplantation from atherosclerotic donor mice into normocholesterolemic recipient 
mice.161 These limitations need to be addressed. 
It will be important in future studies to determine the mechanisms that convert 
saturate sites to non-saturable sites and the potential causal importance of this for the 
onset of atherogenesis. Binding of LDL to intimal proteoglycans is an important step 
in atherosclerosis initiation,134 and saturation of binding sites in the 
glycosaminoglycan-chains of intimal proteoglycans may be the mechanism underlying 
saturation in the intermediate-susceptible area of the central inner curvature region. It 
is also known that LDL retention mechanisms shift once lesions are initiated. Direct 
binding of LDL-ApoB to proteoglycans gradually loses importance, and other types of 
retention that involve the LDL lipid moiety take over, such as binding to lipoprotein 
lipase (LPL)142 and enzyme-catalyzed aggregation (e.g secretory sphingomyelinase 
(S-SMase)).128 Indeed, during the pre-atherosclerotic phase, LPL is mostly localized 
in the arterial media, but once lesions start to become established, it begins to be 
widely distributed in the intimal extracellular matrix secreted by the accumulating 
macrophage foam cells.164 The LPL bound to the intimal proteoglycans then promotes 
the retention of LDL acting as a molecular bridge, especially when LDL are extensively 
oxidized and therefore cannot bind directly to the glycosaminoglycan-chains because 
of the reduced number of positive charges.142 Similarly, secretory acid S-SMase starts 
to appear once lesions develop and promotes LDL retention by inducing lipoprotein 
aggregation and thereby enhanced uptake by macrophages and decreased efflux 
from the artery wall of the large LDL aggregates.128 Combined, these mechanisms 
may have a higher capacity to retain LDL in the intima than LDL-ApoB-proteoglycan 
binding alone. Also, potentially important is the increase in intimal distribution volume 
for incoming LDL in plaques compared with non-diseased arteries.  
Understanding how LDL retention shifts from a low-capacity, saturable process 
to a high-capacity, non-saturable process during the initiation of atherosclerosis is an 
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5.6. Synthesis of findings in a model 
Overall, our combined results lead us to propose the model shown in Figure 36 
for the processes governing LDL accumulation and atherosclerosis onset in the inner 




Figure 36. Model depicting the dynamics of LDL entry and retention in the aortic arch of normal, 
pre-atherosclerotic, and lesioned arteries. OZ= Outer zone; BZ= Border zone; CZ=central zone. The 
OZ has low LDL entry (red) and retention (green) and does not develop atherosclerosis. The BZs have 
high LDL entry and retention and are the sites in which atherosclerosis initiates. The CZ has moderate 
LDL entry and saturable retention, and it develops atherosclerosis at more advanced stages of the 
disease as the saturation of LDL retention is gradually lost. 
In normal arteries, the capacity for LDL retention is sufficient across the entire 
inner curvature region, but after induction of hypercholesterolemia the capacity for 
retaining LDL becomes saturated in the central inner zone while it continues 
unimpeded in the border zones. These border zones are also characterized by high 
levels of LDL entry and early macrophage presence, and they are the first sites to 
develop atherosclerotic lesions. The central inner zone is initially protected by 
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atherosclerosis, but it eventually develops it as the saturation of LDL retaining 
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This doctoral thesis provides a detailed analysis of the rates of LDL entry and retention 
in the mouse aortic arch in the normal physiological state and during early 
atherogenesis. In summary, the following conclusions can be extracted from the 
experiments: 
1. LDL accumulation in PCSK9-induced hypercholesterolemic mice precedes 
the initiation of lesions in a pre-atherosclerotic phase that marks the region 
that will eventually develop atherosclerosis. 
 
2. High-resolution maps of the rates of LDL entry and retention can be 
achieved through in vivo injection in mice of labeled LDL followed by 
quantification and topography evaluation by en face infrared (IR) scanning 
or whole-mount confocal microscopy.  
 
3. Rates of LDL entry and retention are dissociated in normal and pre-
atherosclerotic mouse aortic arch. The pre-atherosclerotic aortic arch has 
higher rate of total labeled LDL entry but lower rate of total labeled LDL 
retention compared with normal arteries. Also, total LDL entry rates in the 
aortic arch increase during the pre-atherosclerotic phase, but this is not 
paralleled by similar increases in total LDL retention rates. Both 
observations indicate that the rate of LDL retention, not that of LDL entry, is 
the limiting factor for total LDL accumulation in the pre-atherosclerotic 
phase. 
 
4. The differences in LDL entry and retention rates across the aortic arch divide 
it into three regions that respond differently to high plasma LDL levels: an 
outer arch zone with low LDL entry and low LDL retention, a central inner 
arch zone with moderate LDL entry and saturated, moderate LDL retention, 
and a border inner arch zone with high LDL entry and non-saturated, high 
LDL retention.  
 
5. The aortic arch zones distinguished by the LDL entry and retention 
measurements predict the development of atherosclerosis. The border 
zones have high susceptibility, the central inner zone intermediate 
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susceptibility and the outer zone low susceptibility to the development of 
atherosclerosis.  
 
6. In the normal vasculature, the pattern of LDL entry predicts the sites that will 
first initiate atherogenesis if LDL levels are increased, whereas the pattern 
of LDL retention predicts the surface area that will eventually be covered 
with atherosclerotic lesions. 
  
7. The saturation of the central inner arch zone that limits LDL accumulation in 
the pre-atherosclerotic phase is not explained by simple competition from 
high levels of plasma LDL but involves limiting retention mechanisms within 
the artery wall. 
  
8. The onset of atherosclerosis is accompanied by a conversion from saturable 
to non-saturable LDL retention.  
 
The study raises new questions about the mechanisms that control LDL entry and 
retention across the three regions of the aortic arch with differing atherosclerosis 
susceptibility, including in particular the retention mechanism that is saturated in some 
parts of pre-atherosclerotic arteries and why this limitation to LDL accumulation is lost 
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A lo largo de la presente tesis doctoral se ha desarrollado un exhaustivo análisis de 
las tasas de entrada y de retención de LDL en el arco aórtico del ratón, tanto en 
condiciones fisiológicas normales como durante estadíos tempranos de la 
enfermedad aterosclerótica. A continuación, se presentan las principales 
conclusiones extraídas a partir de los experimentos realizados:  
1. La acumulación de LDL en ratones con hipercolesterolemia inducida 
mediante la sobreexpresión de PCSK9 precede a la iniciación de las 
lesiones en una fase “pre-aterosclerótica”, señalando la región que 
terminará desarrollando la placa. 
 
2. La inyección in vivo de ratones con partículas de LDL marcadas permite la 
generación de mapas de alta resolución, ilustrativos de la entrada y de la 
retención de dichas lipoproteínas, a través de la cuantificación y análisis 
topográfico mediante el escaneo en infrarrojo de muestras en face o de 
microscopía confocal del tejido completo. 
 
3. Las tasas de entrada y de retención de las LDL en el arco aórtico del ratón 
están disociadas en la fase normal y en la pre-aterosclerótica. En esta 
última se encontró una tasa de entrada de LDL marcado mayor, pero 
menores tasas de retención que en la aorta normal. Además, la tasa de 
entrada en el arco aórtico de LDL totales se incrementa durante la fase pre-
aterosclerótica, pero ello no se ve reflejado en incrementos similares en 
tasas de retención de LDL totales. Ambas observaciones indican que es la 
tasa de retención, y no la de entrada, el factor limitante para la acumulación 
de LDL total en la fase pre-aterosclerótica. 
 
4. Las diferencias en la tasa de entrada y de retención de las LDL a lo largo 
del arco aórtico dividen a este en tres regiones por su diferente respuesta 
a niveles altos de LDL en plasma: una zona del arco externo con baja 
entrada y retención; una zona central interna del arco interno con entrada 
moderada de LDL, así como moderada pero saturada en su retención, y 
una zona fronteriza del mismo con elevada entrada de LDL y alta retención 
no saturada. 
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5. Las regiones del arco aórtico caracterizadas por una diferente entrada y 
retención de partículas de LDL predicen el desarrollo de la aterosclerosis. 
Las regiones fronterizas poseen una elevada susceptibilidad, mientras que 
la zona central interna es moderadamente susceptible a estos procesos, y 
la externa posee una baja tendencia al desarrollo de aterosclerosis. 
 
6. En la vasculatura normal, el patrón de entrada de las partículas de LDL sirve 
para predecir los sitios que prioritariamente iniciarán la aterogénesis si los 
niveles de LDL se incrementan, mientras que el patrón de retención es 
capaz de predecir el área superficial que finalmente podrá desarrollar 
placas de aterosclerosis. 
 
7. La saturación de la región central del arco aórtico interno que actúa como 
limitante en la acumulación de LDL en la fase pre-aterosclerótica no se 
explica por simple competición entre elevados niveles de LDL en el plasma 
sanguíneo, pero sí involucra mecanismos limitantes de la retención dentro 
de la pared arterial. 
 
8. El comienzo de la aterosclerosis se encuentra acompañado de una 
conversión del área desde una retención saturable a otra no saturable por 
partículas de LDL. 
 
El presente estudio plantea nuevas cuestiones sobre los mecanismos que controlan 
la entrada y la retención de las partículas de LDL a lo largo de las tres regiones del 
arco aórtico con una diferente susceptibilidad al desarrollo de la aterosclerosis, 
incluyendo en particular qué mecanismos de retención se saturan en algunas 
regiones de la arteria pre-aterosclerótica, y por qué esta limitación de acumulación de 
LDL se pierde una vez la aterogénesis comienza. 
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